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Abstract 
No evidence-based guidelines exist on the treatment of chronic osteomyelitis of long 
bones in adults. Management is still largely based on expert opinion and consensus 
guidelines are not available. Choosing between a palliative and curative treatment 
strategy requires consideration of several factors. Principle amongst these is the 
host’s physiological status, which determines the patient’s ability to cope with the 
rigours of limb salvage surgery. This fact was recognized by Cierny and Mader, 
when they developed their popular staging system. The authors suggested palliative 
treatment in C-hosts, who will not be able to cope with the metabolic demands of an 
aggressive treatment plan. The problem however, is that the C-host was never 
accurately defined. Cierny and Mader predicted in their original paper that, as a 
result of the inadequate definition, the selection of surgical candidates would vary 
from institution to institution until there was standardization of this concept. 
The limitations of existing classification systems prompted the development of a 
novel approach to chronic osteomyelitis for use in South Africa. This involved the 
establishment of an objective definition of a C-host, as well the development of a 
novel classification system and an algorithmic guideline to treatment strategy 
selection. By integrating the physiological status of the host (based on pragmatic 
predefined criteria) with the selection of the appropriate curative, palliative or 
alternative treatment strategy we were able to achieve favourable short term 
outcomes in both low and high risk cases and in addition reduce the rate of 
amputation. Furthermore, we were able to report novel data on the outcome of 
!vii
palliative treatment, as well as the outcome of treatment of chronic osteomyelitis in 
HIV infected patients. 
While the preliminary results appear promising, long term follow-up will be required 
in order to determine the rate of recurrence of infection. The proposed approach was 
designed specifically with the South African clinical environment in mind and 
additional development of the algorithm may be required in order to render it useful 
in other clinical settings. The implementation of a refined host stratification, which 
incorporates objective criteria for C-host classification will, however, enable the 
comparison of results from studies employing different therapeutic interventions in 
the future. In addition, selection of patient-matched treatment options closes the gap 
in successful outcomes between healthy and compromised patients. The major 
benefit of the proposed approach is therefore the fact that the integrated approach 
places appropriate emphasis on the importance of host factor modification prior to 
surgical intervention.  
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Study development and rationale 
Conceptualization 
In 2009 the author assumed duties at the Tumour, Sepsis and Reconstruction Unit at Grey’s 
Hospital in Pietermaritzburg, KwaZulu-Natal, South Africa. Over a period of approximately 
two years several shortcomings were identified in the existing chronic osteomyelitis 
classification systems. In addition, it was recognized that these classifications may require 
adaptation in order to remain relevant in the developing world. It appeared that in a relatively 
under-developed region one was dealing with a higher proportion of C-hosts than authors in 
the USA, for example. The most popular classification system at the time (published by 
Cierny and Mader) recommended conservative management in C-hosts and curative treatment 
in A and B-hosts.1  
When taking into account that an A-host was seen as a patient without any risk factors and 
that B-hosts were all patients who were neither an A or C-host, it stood to reason that the 
definition of a C-host had important implications in terms of treatment strategy selection. This 
created the need to seek clarity regarding the definition of a C-host, but existing definitions 
were found to be lacking and were not sufficiently concise. The lack of standardization of 
concepts and definitions rendered the teaching the principles of management to orthopaedic 
trainees particularly problematic. In addition, the lack of conformity prohibited the direct 
comparison of results from different studies on interventions in chronic osteomyelitis. 
Our resource poor clinical environment also created other unique challenges. Owing to a lack 
of theatre time some patients were placed on interim chronic suppressive antibiotic therapy, in 
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an attempt to control symptoms while they were awaiting surgery. Many patients responded 
well and preferred not to undergo surgery following the initial therapy. It therefore appeared 
that both curative and palliative treatment strategies could deliver acceptable results, but there 
were still no clear guidelines in the literature regarding selection of the appropriate strategy. 
Apart from the lack of theatre time, plastic surgery was not readily available. This further 
increased the need for accurate host stratification. Without the facility for complex soft tissue 
reconstruction it was important to avoid aggressive surgery in cases where soft tissue cover 
was expected to be problematic. 
In addition to the problems with host stratification, the existing classification systems did not 
provide for new treatment strategies. The induced membrane technique for example, 
popularized by Masquelet, was not included as a treatment option in the Cierny and Mader 
system. These shortcomings combined to identify the need for a novel approach to chronic 
osteomyelitis. The ideal approach would integrate patient classification with treatment 
strategy selection and also allow for the incorporation of contemporary concepts and 
management options. 
Study Setting 
This research was carried out at Grey’s Hospital, which functions as a tertiary referral centre 
for all hospitals within the western inland region of the province of KwaZulu-Natal, South 
Africa. This 525 bed hospital serves a population of approximately 4 million, in a 
predominantly rural setting. Socio-economically underdeveloped regions, like South Africa, 
carry a particularly heavy burden in terms of the prevalence of osteomyelitis.2 This may be 
attributed to, amongst other factors, the high incidence of osteomyelitis in childhood, 
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immunosuppression, malnutrition and the high incidence of trauma. The high prevalence of 
trauma in South Africa is clearly illustrated by the fact that interpersonal violence and road 
traffic accidents were the 2nd and 4th most common causes of death in South Africa in the 
year 2000.3 The road traffic accident fatality rate in South Africa (39.7 per 100 000 
population) is higher than in any other WHO region and almost double the world average.4 
These statistics imply a correspondingly high morbidity related to road traffic accidents, 
which may consequently contribute to an increased incidence in post-traumatic osteomyelitis.  
In addition to a high trauma load, South Africa is faced with a critical shortage of orthopaedic 
surgeons. In developed countries like the USA and Canada, staffing figures range from 4.8 to 
5.6 full-time equivalent orthopaedic surgeons per 100 000 population.5,6 In contrast, during 
2011 there were a mere 0.37 full-time orthopaedic surgeons per 100 000 population working 
in the public sector in the interior of the KwaZulu-Natal province. This shortage in qualified 
orthopaedic surgeons resulted in many patients with skeletal trauma, and more specifically 
compound fractures, not receiving timeous and/or appropriate treatment.  
The final unique characteristic of the setting in which these studies was performed, was the 
high prevalence of HIV infection in the area. In the province of KwaZulu-Natal an estimated 
21.5% of adults between the ages of 15 and 49 years have been infected with HIV.7 The high 
prevalence of HIV may possibly have contributed to an increased incidence of post-traumatic 
chronic osteomyelitis. The main problem was however, that there were no specific guidelines 
available with regard to the management of chronic osteomyelitis in HIV patients.  
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Study Aims 
The aim of this research project was to develop a novel approach to adult chronic 
osteomyelitis that, in a resource poor clinical setting, could guide selection of the appropriate 
treatment strategy. The resulting classification system and treatment algorithm would ideally 
integrate all relevant risk factors, a refined host stratification system and rationalized 
characterization of the pathoanatomy, as well as the realistic goal of treatment. 
Primary objectives 
• To review the pathophysiology of chronic osteomyelitis with specific reference to the 
immunological basis of disease. 
• To compare existing classification systems and identify possible shortcomings. 
• To review the contemporary treatment of chronic osteomyelitis and introduce certain 
additional concepts that may be relevant to the development of a novel approach. 
• To establish the importance of patient selection in achieving success in curative 
treatment strategies. 
• To evaluate the outcome of a novel approach to adult chronic osteomyelitis in South 
Africa. In order to achieve this objective the following was required: 
- Proposal of a new host stratification model, relevant to the South African clinical 
setting, which included discrete criteria that would enable the user to objectively 
stratify the patient’s host status. 
- To propose a revised version of the pathoanatomical section of the classification 
of chronic osteomyelitis in order to rationalize treatment strategy selection. 
- To develop guidelines according to which the classification of patients and 
treatment strategy selection should be integrated. The objective was to establish 
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an algorithm which could guide the treating surgeon to the appropriate treatment 
strategy in accordance with the classification of the patient.  
- To determine, both retro-and prospectively, the efficacy of the proposed 
integrated approach in achieving control of infection in adult chronic 
osteomyelitis. 
Secondary objectives 
• To determine the outcome of palliative treatment of adult chronic osteomyelitis. 
• To determine the outcome of palliative treatment in patients with chronic 
haematogenous osteomyelitis. 
• To determine the outcome of treatment in HIV positive patients. 
Structure of Thesis 
This document is a thesis by publication and comprises five parts. Each part consists of 
chapters containing the relevant publications. These publications have either been published, 
are currently under review or will be submitted for publication.  
• Introduction: The introduction includes a single chapter, which provides the 
background to the research and identifies certain factors that represented obstacles to 
the development of an integrated approach. 
• Part One: Here, the pathophysiology and classification of chronic osteomyelitis is 
reviewed. Chapter two evaluates the pathophysiology, with specific emphasis on the 
osteoimmunology relevant to chronic osteomyelitis. The immunological basis of the 
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disease not only has implications for the definition of the clinical entity, but also 
emphasizes the importance of the host’s immunological competency in the treatment 
of the disease. Chapter three assesses existing classification systems, illustrating their 
limitations and identifying areas requiring improvement. 
• Part Two: Two chapters are in included that deal with the management of chronic 
osteomyelitis. Chapter four and five review all treatment modalities available and 
attempt to discern areas were existing treatment guidelines fail to consider all relevant 
concepts or treatment options. 
• Part Three: Here we illustrate the importance of accurate host stratification in 
treatment strategy selection. This part focuses on the implementation of a curative 
treatment strategy involving wide resection and bone transport through an induced 
membrane. Patient selection is identified as an important factor in ensuring a 
successful outcome of this complex procedure.  
• Part Four: This part consists of a retrospective evaluation of the efficacy of the 
proposed integrated approach. The paper which makes up this chapter is the first to 
report the outcome of palliative treatment strategies in conjunction with curative 
treatment outcomes. It allows for the development of a more comprehensive picture of 
the validity of the proposed approach, in contrast to previous reports which focused on 
the outcome of curative strategies. Novel information is garnered regarding the 
management of chronic osteomyelitis in HIV positive patients and the outcome of 
palliative treatment in patients with chronic haematogenous osteomyelitis. 
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• Part Five: The final part of the thesis consists of a prospective assessment of the 
outcome of treatment according to the proposed integrated approach.  
• Conclusion: This chapter provides a summary of the entire thesis, highlights the 
limitations of the studies presented and identifies areas for possible future research.  
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Chapter 1: Introduction 
1.1. Background 
Despite the numerous advances in antibiotic therapy and operative intervention, chronic 
osteomyelitis remains challenging to treat.1 In fact, absolute cure from the disease is 
considered to be an unrealistic goal and most authors prefer to use terms like “arrest” or 
“remission” rather than “cure” or eradication” .2 When analyzed at its most elementary level, 
the management of adult chronic osteomyelitis is based on a choice between either a palliative 
or curative approach.3 Curative treatment, aimed at remission of disease, typically involves a 
combination of complex surgical procedures and tailored adjuvant antibiotic therapy.4 
Palliative treatment, on the other hand, is less invasive and typically involves to the use of 
chronic suppressive antibiotic therapy.5 Although the decision to operate or alternatively to 
select a non-operative treatment strategy is a dilemma frequently faced by orthopeadic 
surgeons, it is particularly problematic in chronic osteomyelitis. Selecting the incorrect 
strategy may have devastating consequences. Embarking on a curative limb salvage protocol 
which involves extensive debridement resulting in a large bone defect, for example, may 
result in an unwanted amputation if the patient is unable to withstand the rigours of the 
reconstructive process.   
No evidence-based guidelines have previously been published in terms of the selection of the 
appropriate treatment strategy in patients with chronic osteomyelitis.3 The treatment of 
osteomyelitis remains largely based on expert opinion and no consensus guidelines are 
available.6 Choosing between a palliative and curative treatment strategy requires 
consideration of several factors, principle amongst which is the host’s physiological status. 
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This was recognized by Cierny and Mader when they included the physiological status of the 
host in their staging system which was aimed at guiding treatment selection.7 The authors 
suggested palliative strategies involving observation, antibiotic therapy, orthosis and/or 
compressive garments in C-hosts.7 The problem however, is that the C-host was never 
accurately defined. Cierny and Mader predicted in their original paper that, as a result of the 
inadequate definition, the selection of surgical candidates would vary from institution to 
institution until there was standardization of this concept.7 
With a lack of clear guidelines the selection of the appropriate treatment strategy remains 
difficult, especially amongst training doctors who are inexperienced in the management of 
chronic osteomyelitis. This is a result of the fact that treatment selection, according to the 
Cierny and Mader system, is based on the physician’s ability to predict the patient’s capacity 
to cope with the metabolic demands of an aggressive treatment plan. In addition, the lack of 
standardization has prohibited the comparison of results of studies investigating different 
therapeutic interventions. Many studies focussing on antibiotic therapy included patients with 
and without surgical implants, as well as cases which did and did not have surgical 
debridement. This lack of uniformity makes comparison of results difficult and illustrates the 
need for the establishment of standardized nomenclature and definitions. 
1.2. Obstacles to the development of an integrated approach 
Taking the above-mentioned limitations into account, it would be ideal to establish a 
standardized, unified approach which integrates the realistic goals of treatment, all relevant 
risk factors (psychosocial, physiological and local), the anatomic nature of the disease, and 
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allows selection of the appropriate treatment strategy through a rational algorithmic process. 
Such an integrated approach could serve as a useful treatment guideline for surgeons less 
experienced in managing chronic osteomyelitis. In addition, standardization of host staging 
and treatment selection would enable the comparison of results from interventional studies. 
There were however, several obstacles to the development of such an integrated approach: 
1.2.1. The definition of chronic osteomyelitis in adults 
There is currently no uniform clinical definition (in the English language) for the diagnosis of 
chronic osteomyelitis and most authors are left to define their own diagnostic criteria.8 In 
order to propose a universally applicable definition, the pathogenesis as well as the 
bacteriological and immunological basis of the disease has to be considered.  
Chronic osteomyelitis is characterized by the progressive inflammatory destruction of bone, 
followed by the apposition of new bone as part of the reparative process. Traditionally, 
chronic osteomyelitis was therefore defined by the presence of sequestrum and involucrum. 
Although this definition remains applicable in terms of chronic haematogenous osteomyelitis, 
it fails to address certain clinical scenarios found in contiguous post-operative, post-traumatic 
and implant-related infections. As a result, Cierny proposed a definition more appropriate in 
the setting of contemporary orthopaedics.9 He defined chronic osteomyelitis as a biofilm-
based infection where the majority of pathogens are sessile-based and are resiliently attached 
to necrotic bone, surgical implants or foreign material. This definition is not restricted to the 
cause, the presence of surgical implants, nor to the anatomic nature or duration of the disease, 
but rather defines it by the presence of a universally applicable pathogenesis. The concept of 
chronic osteomyelitis is thus currently understood to include a wide variety of clinical 
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scenarios, including haematogenous, contiguous, post-traumatic and post-operative infections. 
Certain aspects of this definition can however be explored further.  
Taking the pathogenesis of arthroplasty-related periprosthetic infections into account, it could 
(when applying Cierny’s definition) be classified as a type of chronic osteomyelitis. In this 
thesis, periprosthetic infections have been excluded from the discussion, based on the current 
trend of classifying and treating arthroplasty-related infections as a separate entity.10  
Another question which arises from the definition proposed by Cierny relates to the entity 
known as minimal necrosis osteomyelitis.7 Although Cierny and Mader recognized this entity 
in their original publication, they did not include it in their classification system and 
furthermore, the concept does not fit into the definition proposed by Cierny in 2011.9 In the 
case of minimal necrosis osteomyelitis, the absence of necrotic bone makes the definition 
proposed by Cierny less relevant. In these cases, the pathophysiology of the infection may 
also involve other characteristics of the causative organisms, including the ability of small 
colony variants to persist intra-cellularly for extended periods of time. A definition based on 
the duration of infection may therefore also be relevant as it would remain applicable, 
irrespective of the cause of infection or presence of a sequestrum or implant. However, this 
raises questions regarding the timescale of biofilm formation, which will be explored further 
in Chapter 9.  
The final issue surrounding the definition of chronic osteomyelitis relates to the age of the 
patient. Paediatric chronic osteomyelitis is seen as a separate entity and Cierny and Mader 
recognized this when developing their classification for use in adults.7 One notable difference 
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in the management of chronic osteomyelitis in children is that in certain instances sequestra 
are left in place in order to allow for adequate new bone formation prior to surgical 
intervention.11,12 This strategy may be successful in the paediatric population because children 
have a much greater potential to resorb sequestra and to form adequate involucrum, but it is 
unlikely to be successful in adult cases. Owing to these differences the author has adopted the 
same approach as most authors on the topic, by excluding paediatric patients (below the age 
of 14 years) from the study. 
1.2.2. The indications for surgery 
Factors which have previously been recognized to have an influence in the selection of 
treatment in adults with chronic osteomyelitis, include the functional impairment caused by 
the disease, the anatomical nature of the pathology, the reconstruction options available and 
the metabolic consequences of aggressive therapy.7 Other factors may however also need to 
be considered, for example the social circumstances of the patient (which may influence their 
ability to comply with the requirements of a specific treatment protocol), the presence of 
psychiatric illness and the realistic goal of treatment.  
A draining sinus associated with minimal pain or dysfunction is not, in itself, an indication for 
surgical treatment.9 At times, procedures aimed at achieving arrest of the disease are of such 
magnitude that the consequences can prove to be more disabling than the disease itself and 
the treatment can lead to loss of function, limb, or life.7 The decision to pursue a curative 
treatment strategy is thus based on the assessment of the risk/benefit ratio in each patient. 
Curative treatment must offer distinct advantages over palliative care and the risk profile of 
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the proposed surgical treatment should be low.9 Ultimately, quality of life remains the  
priority.7 
While surgical intervention in a patient who is unable to cope with the physical and 
physiological demands of the reconstructive procedure should be avoided, leaving chronic 
osteomyelitis untreated may (in rare cases) also have serious consequences. Secondary 
amyloidosis has been reported in 10% of patients with long standing suppurating 
osteomyelitis.13 Secondary (Amyloid A) amyloidosis most commonly results in proteinuria, 
renal insufficiency, or nephrotic syndrome. 14 Amyloid deposits may also cause hepatomegaly, 
splenomegaly and gastrointestinal manifestations including motility disturbances, 
malabsorption, bleeding or perforation. In approximately 5% of patients with secondary 
amyloidosis, cardiac involvement may cause heart failure. Secondary amyloidosis however, 
typically only develops when the causative chronic infection or inflammatory disease has 
been present for a long time; a median period of 17 years in one series.15 In addition the 
amyloid deposits are absorbed when the suppuration is controlled or removed.13  
The second life-threatening condition that may result from long-standing uncontrolled chronic 
osteomyelitis is the development of a Marjolin’s ulcer or squamous cell carcinoma.16 Other 
malignancies, fibrosarcoma for example, have also been reported in the vicinity of long-
standing chronic osteomyelitic lesions.17,18 The development of these cancers is however a 
slow process. Typically chronic discharging osteomyelitis has to be present for at least 12 to 
35 years prior to the development of a malignancy.19 Furthermore, this serious complication 
can be prevented by adequate wound coverage or wound healing.16  
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Although the above-mentioned complications are serious and even life threatening, it appears 
that they only develop in cases involving long-standing periods of uncontrolled infection. 
Therefore the risk of these complications can be minimized by achieving suppression of the 
disease through a successful palliative strategy and is therefore not necessarily an indication 
for surgery in patients with chronic osteomyelitis.  
Clearly the decision to embark on a curative or palliative strategy is a difficult one, with many 
factors to consider. The Cierny and Mader classification system was aimed at facilitating this 
process and recommended curative (surgical) treatment in A and B-hosts and palliative 
treatment in C-hosts. The definition of the C-hosts is therefore critical as it forms the basis of 
treatment strategy selection. As stated previously, the main problem faced (in terms of 
treatment selection) was the absence of pragmatic diagnostic criteria defining a C-host. 
1.2.3. The definition of a C-host  
While bacterial infection may initiate the disease, the majority of the clinical and radiological 
sequelae of chronic osteomyelitis are the result of a patient’s immune response to the 
infection.20 The patient’s immune response is also an important role-player in effecting 
remission of the disease. Without a competent immune response or the necessary healing 
potential, any attempt at the eradication of infection may be compromised.21 The patient’s 
immunological and physiological status is, therefore, a critical factor to consider when 
contemplating a curative treatment strategy.  
In 1985 the Cierny and Mader classification system (also known as the University of Texas 
Medical Branch or UTMB classification) recommended curative treatment in A and B-hosts 
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and suppressive or no treatment in C-hosts.7 In 2011 Cierny again recommended that C-hosts 
be palliated or simply treated expectantly.9 Walter and co-workers also recognized the validity 
of both curative and palliative treatment pathways.3 They however did not provide guidelines 
in terms of how a specific treatment strategy should be selected.  
The definition of a C-host (i.e., the patient who should be palliated) is critical as it forms the 
basis of treatment strategy selection. Objective and discreet diagnostic criteria, defining a C-
host, has not previously been established. Cierny and Mader defined a C-host as a patient in 
whom treatment or results of treatment are more compromising than the disability caused by 
the disease itself.7 Their definition encompasses a large group of patients, which includes 
patients with minimal disability as well as patients who are not suitable candidates for 
complex bone and/or soft tissue reconstruction. The main shortcoming in this definition 
remains the fact that it is susceptible to widely varying interpretation depending on the 
surgeon’s experience. Cierny and Mader recognized the limitations of their definition of a C-
host and predicted that the selection of surgical candidates would vary from institution to 
institution until there was standardization of the concept.7 Therefore, in order to develop an 
integrated approach to adult chronic osteomyelitis, which incorporates treatment strategy 
selection guidelines, the definition of a C-host would have to be refined. 
1.2.4. The definition of cure 
Another obstacle to the comparison of results of previous studies and the development of an 
integrated approach, was the lack of a consensus definition of cure in chronic osteomyelitis.22 
Lazzarini et al. came to a similar conclusion when they reviewed the outcome of antibiotic 
therapy in osteomyelitis.6 They were obliged to adopt their own definition of cure because 
!16
different definitions of a successful outcome were used in the 93 studies included in their 
review.  
While clinical evidence of osteomyelitis may be relieved (in certain cases) by antibiotic 
therapy alone, symptoms and signs are likely to recur in many patients if the source of the 
infection is not surgically addressed. The surgical margin elected by the surgeon also has 
important implications in terms of the outcome. Cure, in the strictest sense of the word, can 
theoretically only be attained through wide resection of all necrotic, ischemic and infected 
tissue.21  
Marginal debridement involving direct or indirect unroofing, avoids compromising skeletal 
stability but may leave infected bone behind. The offending bacteria may evade host defences 
or antibacterial agents by persisting intracellularly or by entering a metabolically inactive 
state within the biofilm.23 As a result, clinically evident infection may recur years later, in 
certain cases more than 50 years after the initial episode.24,25 In cases where marginal 
debridement is employed, “cure” is therefore an unrealistic expectation and “remission”, 
“arrest” or “quiescence” would be more appropriate terminology.3 In order to allow better 
comparison of studies in chronic osteomyelitis, standardization of the concept of a successful 
outcome thus need to be established. 
Different criteria may be required in respect of the definition of a successful outcome in cases 
treated palliatively and curatively. While arrest or remission would be a reasonable goal for a 
curative treatment strategy, the same outcome cannot be expected of a palliative protocol. 
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Palliative treatment strategies aim to suppress the disease.26,27 Successful suppression has 
however, not yet been defined.  
1.3. Other unresolved issues  
An integrated approach to chronic osteomyelitis, which incorporates a rationalized host 
stratification system, could be of benefit to orthopaedic surgeons inexperienced in the 
management of chronic osteomyelitis. An algorithm-like approach would be especially useful 
in underdeveloped regions where surgeons frequently do not have access to specialized 
infection units or multi-disciplinary teams. Furthermore, surgeons working in resource-poor 
clinical environments are frequently faced with additional challenges like a high prevalence of 
HIV infection or other risk factors which might result in C-host classification. The 
development of an integrated approach to chronic osteomyelitis, aimed at assisting decision 
making in a developing country, would therefore require consideration of the outcome of 
treatment in C-hosts or in patients living with HIV. Unfortunately there has, to date, been very 
little information published regarding chronic osteomyelitis in HIV positive patients. In 
addition, the outcome of palliative treatment has not been established.  
1.3.1. The results of palliative treatment strategies 
Chronic osteomyelitis in adults is particularly challenging to treat. In specialized bone 
infection units success rates of curative treatment strategies varies from 70% to 90%.3,28 
Cierny reported an 85% success rate of curative treatment at two year follow-up, with 96% 
success in A-hosts and 74% in B-hosts.9 Ten percent of cases in his series were managed by 
primary amputation. The Bone Infection Unit in the United Kingdom reported an excellent 
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cure rate of 90% at five years follow-up (though the amputation rate was not mentioned).29 
Both of these articles are review articles and the authors reported only briefly on their 
outcomes as an illustration of the potential prognosis. Neither reported the outcome of 
treatment in the palliative group. In fact, there are very few reports of the outcome of 
palliative treatment in chronic osteomyelitis. The paucity in the literature, in terms of the 
outcome of palliative treatment, is particularly prominent in the case of chronic 
haematogenous osteomyelitis. Lazzarini et al. have previously drawn attention to the fact that 
the efficacy of suppressive treatment of long-bone osteomyelitis, without an implant in place, 
has not been determined.26  
The majority of studies looking at the outcome of chronic suppressive antibiotic therapy 
(CSAT) involved patients with periprosthetic joint infections and not chronic osteomyelitis of 
long bones.30-33 Some of the earlier reports investigating the efficacy of CSAT in 
periprosthetic infections included patients with infected osteosynthesis implants. Stein et al. 
reported a “cure” rate of 60% in patients treated with antibiotics without surgical removal of 
the implants.34 The authors did not distinguish between joint replacement and osteosynthesis 
implant-related sepsis when reporting these results. An earlier study from the same authors 
reported “cure” in six of the nine patients with osteosynthesis implant related sepsis who were 
treated with antibiotics alone for a period of six months.35 
Other studies investigating the efficacy of certain antibiotics, also included patients treated 
palliatively. These articles were, however, written mostly from an infectious disease 
viewpoint and often did not report on how patient classification or treatment strategy selection 
was performed. This was clearly illustrated by Spellberg and Lipsky, who found that only two 
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of the 17 non-randomized trials investigating cure rates of parenteral antibiotic agents in 
chronic osteomyelitis, reported specifically on the use of concomitant surgical debridement.22 
In the first of these studies, four out of the eight patients who did not receive surgery were 
“cured”.36 Thirteen of the 34 patients enrolled in the second study (involving intravenous 
imipenem/cilastatin therapy) were managed without surgical debridement.37 The authors 
however did not specifically report the outcome in patients who did not receive surgery. 
Spellberg and Lipsky also found that none of the 18 studies looking at the efficacy of 
fluoroquinolones reported cure rates in patients who did and did not undergo debridement.22 
Saengnipanthkul et al. reported a 45% cure rate using	  trimethoprim-sulfamethoxazole to treat 
66 patients with chronic osteomyelitis, only 55% of whom underwent surgical debridement. 
Cure rates in patients who did not receive debridement were not reported independently.38 
Similarly, Javaloyas de Morlius and Monreal Portella did not report the outcome separately in 
the six patients who did not receive surgery in their series.39 Lazzarini et al. reviewed the 
outcome of antibiotic therapy in paediatric and adult osteomyelitis by analysing the results of 
all clinical trials performed over the preceding 30 years.6 However, the authors excluded all 
patients with surgical implants from the start. In addition, the authors were unable to analyse 
the outcome by treatment duration as only a small number of the studies involved prolonged 
treatment.6  
There is therefore very little data available on the outcome of palliative treatment (in the form 
of chronic suppressive antibiotic therapy) in chronic osteomyelitis and none of the studies 
available investigated this issue specifically. Furthermore, none of the above-mentioned 
studies explained how patients were selected for palliative treatment instead of curative 
treatment. In addition, none of the previous authors apart from Cierny and McNally, reported 
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their results with reference to accepted orthopaedic host classification systems.9,29 To justify 
the validity of a classification system, the outcomes of both curative and palliative treatment, 
as well as the amputation rate, would have to be reported. The ideal treatment guidelines for 
adult chronic osteomyelitis should preferably result in comparatively high success rates in 
both the curative and palliative treatment arms, while maintaining a low amputation rate.  
1.3.2. HIV infection and chronic osteomyelitis 
The association between HIV infection and chronic osteomyelitis has not been clearly 
defined. Several conflicting studies have been published. Initial reports noted an increased 
risk of post-operative infection, while more recent studies failed to show an increase in 
infection. 
In 1991 Hoekman et al. found an increase in the risk of post-operative infection following 
surgical fracture fixation in symptomatic (defined as CDC stage III or IV) HIV infected 
individuals.40 Jellis subsequently reported a 33% infection rate following internal fixation of 
closed fractures and a 72% infection rate in open fractures.41 Noteworthy is the fact that Jellis 
noticed an increase in adult haematogenous osteomyelitis and late implant-related infections, 
as patients’ immune competency decreased. In 2002 Harrison et al. found a significant 
increase in early wound infection following open fractures in HIV positive patients.42 The 
incidence of early wound sepsis following internal fixation of closed fractures was however 
not increased in this series. Harrison et al. then investigated the prevalence of late infection 
and found no implant related infection in 26 HIV positive patients at one year follow-up.43 A 
subsequent study from the same center in Malawi again failed to show an increased risk of 
early wound infection following clean surgery, but found that the infection rate had doubled in 
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contaminated wounds.44 Contrary to the findings of Jellis, this study did not show an increase 
in chronic infections in HIV positive patients. Two further studies from KwaZulu-Natal, 
South Africa, added to the controversy. The first noted an increased risk of infection in open 
fractures in patients with advanced HIV disease (CD4 < 350 cells/µl).45 The second study 
failed to show an increase in early wound infection in HIV positive patients with open tibia 
fractures.46  
The evidence available appears to be contradictory in terms of the development of infection in 
both open and closed fractures. However, most of these studies were designed to look at HIV 
as a risk factor for early wound infection rather than the development chronic osteomyelitis. 
Moreover, it is not known if HIV infection resulted in an increased risk of reactivation of 
chronic haematogenous osteomyelitis. Most significantly there is little data available on the 
outcome of treatment of chronic osteomyelitis in HIV positive patients. Some of the 
aforementioned articles simply mentioned the fact that patients who did develop infection 
responded well to standard treatment.40,41 
1.4. Summary 
In conclusion, we have elucidated several issues in the literature which require further 
investigation. These include the absence of standardized definitions, the outcome of palliative 
treatment strategies, as well as the clinical characteristics and results of treatment of chronic 
osteomyelitis in HIV positive patients. In addition the need for the establishment of a 
comprehensive treatment algorithm has been identified. This would however, require 
refinement of existing host stratification and classifications systems in order to ensure 
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objective risk-factor assessment and treatment strategy selection.  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PART 1 
The pathophysiology and classification of chronic osteomyelitis 
The clinical manifestations of chronic osteomyelitis result from the complex interplay 
between the host’s immune defence system and the pathogen attempting to establish a 
biofilm-based colony on a sequestrum or surgical implant.1 Although bacterial infection may 
initiate the patient’s symptoms, there are strong indications that the immune system may 
actually be the strongest contributor to disease and pathology of chronic infections.2 The 
host’s physiological status therefore, not only determines the clinical course of the disease but 
also serves as the primary indicator of the patient’s ability to effect healing of bone and soft 
tissues, as well as their ability to launch an effective immune response in conjunction with 
antibiotic therapy and surgery. Without a competent immune response from the host, any 
attempt at eradication of the infection may be futile.3 
The first paper (Chapter 2) provides an overview of the definition of chronic osteomyelitis, 
the biological behaviour of the causative organisms and the immunological basis of the 
disease. The relatively new field of osteoimmunology sheds light on the importance of the 
host’s immune system in the pathophysiology of the disease. The role of biofilm is also 
discussed as it may have important implications for the definition of the disease, as well as the 
definition of cure.  
Chronic osteomyelitis includes a wide variety of clinical scenarios, including haematogenous, 
post-operative and post-traumatic infections. An accurate definition of the disease entity is 
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required in order to identify cases in whom the proposed algorithm could be deemed 
appropriate. Haematogenous osteomyelitis , although still common in the developing world, 
has been surpassed by post-traumatic or post-operative infection as the leading cause of 
chronic osteomyelitis in adults. The changing face of chronic osteomyelitis has necessitated 
an evolution in the definition of the disease to one that is based on a universally applicable 
pathogenesis. Some questions regarding the suitability of existing definitions remain and 
these issues will be discussed further in Chapter 9. 
The second paper (Chapter 3) provides a critical review of existing classification systems and 
identifies areas that require further development. It highlights the need for accurate host 
stratification and the fact that existing classification systems fail to consider certain 
contemporary reconstructive options. 
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Chapter 2: The pathophysiology of chronic osteomyelitis  
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SRVWWUDXPDWLFRVWHRP\HOLWLV
,Q DGGLWLRQ WR DKLJK WUDXPD ORDG 6RXWK$IULFD LV IDFHG
ZLWKDVHYHUHVKRUWDJHRITXDOLILHGRUWKRSDHGLFVXUJHRQV,Q
GHYHORSHG FRXQWULHV OLNH WKH 86$ DQG &DQDGD ILJXUHV
UDQJH IURP ² IXOOWLPH HTXLYDOHQW RUWKRSDHGLF
VXUJHRQV SHU   SRSXODWLRQ ,Q FRQWUDVW LQ 
SXEOLF VHFWRU PHGLFDO VHUYLFHV LQ WKH LQWHULRU RI WKH
.ZD=XOX1DWDO SURYLQFH LQ 6RXWK $IULFD VHUYHG D
SRSXODWLRQ RI DSSUR[LPDWHO\ PLOOLRQSHRSOHZLWK RQO\
IXOOWLPHRUWKRSDHGLFVXUJHRQVSHUSRSXODWLRQ
7KLVVKRUWDJHUHVXOWVLQPDQ\SDWLHQWVZLWKVNHOHWDOWUDXPD
DQG PRUH VSHFLILFDOO\ FRPSRXQG IUDFWXUHV QRW UHFHLYLQJ
DSSURSULDWHWUHDWPHQWFRQWULEXWLQJWRDIXUWKHULQFUHDVHLQ
WKHFKURQLFRVWHRP\HOLWLVGLVHDVHEXUGHQ
$OWKRXJK WKH DVVRFLDWLRQ EHWZHHQ +,9 LQIHFWLRQ DQG
FKURQLFRVWHRP\HOLWLVKDVQRWEHHQFOHDUO\GHILQHGSUHYLRXV
UHVHDUFK KDV VKRZQ DQ LQFUHDVHG ULVN RI SRVWRSHUDWLYH
LQIHFWLRQIROORZLQJVXUJLFDOIUDFWXUHIL[DWLRQLQ+,9LQIHFWHG
LQGLYLGXDOV 7KH SUHYDOHQFH RI +,9 LQIHFWLRQ LQ 6RXWKHUQ
$IULFD KDV UHDFKHG HSLGHPLF SURSRUWLRQV 0LG\HDU
HVWLPDWHV IRU  DSSUR[LPDWHV WKH QDWLRQDO SUHYDOHQFH RI




WKH ILQDQFLDO LPSOLFDWLRQV RI WKH WUHDWPHQW RI FKURQLF
RVWHRP\HOLWLV 7KH GLUHFWPHGLFDO FRVW DVVRFLDWHGZLWK WKH
PDQDJHPHQW RI RVWHRP\HOLWLV LQ WKH 86$ LQ  ZDV
HVWLPDWHG DW  SHU HSLVRGH ,Q 6RXWKHUQ$IULFD WKH
KLJK FRVW RI WUHDWPHQW LV PXOWLSOLHG E\ WKH PXFK KLJKHU
EXUGHQ RI GLVHDVH SRVLQJ D VLJQLILFDQW FKDOOHQJH WR RXU
UHVRXUFHUHVWULFWHGKHDOWKV\VWHPV
Definition
2VWHRP\HOLWLV LV FKDUDFWHULVHG E\ WKH SURJUHVVLYH LQIODP
PDWRU\GHVWUXFWLRQ RI ERQH IROORZHGE\ WKH DSSRVLWLRQ RI









WKH XVH RI VXUJLFDO LPSODQWV LQFUHDVHG WKH LQFLGHQFH RI
FRQWLJXRXV SRVWRSHUDWLYH RVWHRP\HOLWLV GUDPDWLFDOO\
LQFUHDVHGQHFHVVLWDWLQJUHYLVLRQRIRXUGHILQLWLRQ1RORQJHU
ZDV KDHPDWRJHQRXV VSUHDG FRQVLGHUHG WR EH WKH PDMRU
FDXVHDQGWKHHPSKDVLVVKLIWHGWRZDUGVWKHGXUDWLRQRIWKH
GLVHDVH 7KH GXUDWLRQ RI LQIHFWLRQ WKDW GHILQHG FKURQLFLW\
JUDGXDOO\GHFUHDVHGRYHUWLPHDQGLQLWZDVGHILQHGDV
V\PSWRPV UHPDLQLQJ IRU ORQJHU WKDQ WHQ GD\V $Q







WKH VHWWLQJ RI FRQWHPSRUDU\ RUWKRSDHGLFV +H GHILQHG




LPSODQWV RU IRUHLJQ PDWHULDO DQG HPEHGGHG ZLWKLQ D
JO\FRFDO\[VOLPHELRILOP7KLVUHQGHUVWKHPOHVVVHQVLWLYH
WR V\VWHPLF DQWLELRWLF DJHQWV DQG PDNHV URXWLQH FXOWXUH
WHFKQLTXHV OHVVUHOLDEOH:LWK WLPHWKHEDFWHULDO WR[LQVDQG
E\SURGXFWV RI WKH KRVW·V LPPXQH V\VWHP DFFXPXODWH WR
UHVXOW LQ WKH ORFDO DQG V\VWHPLFPDQLIHVWDWLRQV RI FKURQLF











&HQWUDO WR WKLV XQGHUVWDQGLQJ OLHV WKH FRQFHSW RI EDFWHULDO
ELRILOP,Q*ULVWLQDet alFRLQHGWKHSKUDVH¶WKHUDFHIRU
WKHVXUIDFH· 7KHKRVWFHOOV VWULYHWRHVWDEOLVKDQLQWHJUDWHG
SURWHFWLYH FHOOXODU OD\HU ZLWK IXQFWLRQDO GHIHQFH
PHFKDQLVPV LQFOXGLQJ RSVRQLILFDWLRQ SKDJRF\WRVLV DQG
FRPSOHPHQW PHGLDWHG O\VLV ZKLOH WKH LQYDGLQJ EDFWHULD
HQWHU WKHLUGHIDXOW JURZWKSDWWHUQ DQGHVWDEOLVK DELRILOP
7KLV LV D OD\HUOLNH DJJUHJDWLRQ RI PLFURELDO FHOOV DQG
H[WUDFHOOXODU SRO\PHULF VXEVWDQFHV DWWDFKHG WR D VXEVWUDWH
ZKLFKSURYLGHVDQHQYLURQPHQWIRUWKHH[FKDQJHRIJHQHWLF
PDWHULDOEHWZHHQEDFWHULDOFHOOV
In addition to a high trauma load, South Africa is faced 
with a severe shortage of qualified orthopaedic surgeons
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3DJH16 6$2UWKRSDHGLF-RXUQDO6XPPHU_9RO1R
7KH SUHVHQFH RI D IRUHLJQ ERG\ KDV EHHQ VKRZQ WR
VLJQLILFDQWO\ LQFUHDVH VXVFHSWLELOLW\ WR LQIHFWLRQ )RU
H[DPSOHWKHPLQLPDOLQIHFWLQJGRVHRIStaphylococcus aureus
LVPRUHWKDQIROG ORZHU LQWKHYLFLQLW\RIVXEFXWD
QHRXV GHYLFHV WKDQ LQ VNLQ ZLWKRXW DQ LPSODQW 7KLV
LQFUHDVHG VXVFHSWLELOLW\ WR LQIHFWLRQ LV SDUWLDOO\ GXH WR D
ORFDOO\DFTXLUHGJUDQXORF\WHGHIHFW
%LRILOPIRUPDWLRQRFFXUVLQILYHVWDJHVQDPHO\DGKHVLRQ
SURGXFWLRQ RI WKH H[WUDFHOOXODU PDWUL[ FRORQLVDWLRQ
PDWXUDWLRQDQGILQDOO\GLVSHUVLRQRIEDFWHULD7KHILUVWVWDJH
LQYROYHV DGKHVLRQRI WKHEDFWHULD WR WKH VXEVWUDWH WKURXJK
VSHFLILFDQGQRQVSHFLILFPHFKDQLVPV 6SHFLILFPHFKDQLVPV
LQYROYH WKH H[SUHVVLRQ RI DGKHVLRQ PROHFXOHV NQRZQ DV
DGKHVLQV RU 06&5$00 PLFURELDO VXUIDFH FRPSRQHQWV
UHFRJQLVLQJ DGKHVLYHPDWUL[PROHFXOHV VSHFLILF WR FHUWDLQ
KRVW SURWHLQV OLNH ILEURQHFWLQ ODPLQLQ VLDORJO\FRSURWHLQV
ILEULQRJHQDQGFROODJHQ1RQVSHFLILFPHFKDQLVPV LQYROYH
VXUIDFH WHQVLRQJUDGLHQWVK\GURSKRELFLW\DQGHOHFWURVWDWLF
IRUFHV 2QFH FRQWDFW LV PDGH ZLWK WKH VXEVWUDWH EDFWHULD
PLJUDWH ZLWK WKH DLG RI IODJHOOD XQWLO RWKHU EDFWHULD DUH
HQFRXQWHUHG WKXV HVWDEOLVKLQJ PLFURFRORQLHV 2QFH WKH
PLFURELDOGHQVLW\UHDFKHVDFULWLFDOSRLQWWKHYROXPHRIFHOO
WRFHOO VLJQDO PROHFXOHV UHOHDVHG LV VXIILFLHQW WR DFWLYDWH
JHQHV LQYROYHG LQ WKH SURGXFWLRQ RI DQ H[RFHOOXODU
SRO\VDFFKDULGH RU JO\FRFDO\[ 7KH DELOLW\ RI D PLFURELDO
FRORQ\ WR VHQVH LWV VL]H DQG UHVSRQG E\ DOWHULQJ LWV JHQH
H[SUHVVLRQLVUHIHUUHGWRDVTXRUXPVHQVLQJ7KLVSKDVHRI
ELRILOP IRUPDWLRQ LV EHLQJ LQYHVWLJDWHG DV D WDUJHW IRU WKH
SUHYHQWLRQ RI ELRILOP IRUPDWLRQ RQ RUWKRSDHGLF LPSODQWV
$QLPDO PRGHOV KDYH VKRZQ WKDW WKH TXRUXPVHQVLQJ
LQKLELWRU 51$ ,,,LQKLELWLQJ SHSWLGH FDQ KHOS SUHYHQW
VWDSK\ORFRFFDOELRILOPIRUPDWLRQDQGLQIHFWLRQ
&RQWUDU\ WR SRSXODU EHOLHI EDFWHULD GR QRW GLIIHUHQWLDWH
GXULQJWKHFRORQLVDWLRQSKDVHRIELRILOPIRUPDWLRQEXWUDWKHU
WKH\ DOWHU WKHLU SDWWHUQ RI JHQH H[SUHVVLRQ DQG VKRXOG
WKHUHIRUH EH VHHQ DV LQWHUDFWLYH FRPPXQLWLHV UDWKHU WKDQ D
PXOWLFHOOXODU RUJDQLVP $ VXESRSXODWLRQ RI EDFWHULDPD\
HYROYH LQWR D SKHQRW\SLFDOO\ UHVLVWDQW VWDWH DQG H[SUHVV
ELRILOPVSHFLILFDQWLPLFURELDOUHVLVWDQFHJHQHV2WKHUEDFWHULD
ZLWKLQ WKH ELRILOP PD\ SURGXFH K\GURODVH HQ]\PHV DQG
H[RWR[LQV UHVXOWLQJ LQ ORFDO WLVVXH LQYDVLRQ %LRILOPEDVHG
EDFWHULD KDYH XS WR D  WLPHV JUHDWHU UHVLVWDQFH DJDLQVW
DQWLPLFURELDOVDQGKRVWLPPXQHGHIHQFHV7KLVGHULYHVIURP
D FRPELQDWLRQ RI SKHQRW\SLF PHFKDQLFDO DQG PHWDEROLF
PHFKDQLVPV $QWLELRWLFV IDFH PHFKDQLFDO DQG RVPRWLF
FKDOOHQJHVLQSHQHWUDWLQJDELRILOPZKLOHWKHUHGXFHGJURZWK
UDWH RI EDFWHULDGXH WR LQFRPSOHWHSHQHWUDWLRQ RIPHWDEROLF
VXEVWUDWHV DQG DFFXPXODWLRQ RI ZDVWH SURGXFW PDNHV WKH
ELRILOPEDVHGEDFWHULD HYHQPRUH UHVLOLHQW 7KHVH VRFDOOHG
VPDOO FRORQ\ YDULDQWV DUH FKDUDFWHULVHG E\ VORZ JURZWK
GHFUHDVHG SLJPHQW IRUPDWLRQ ORZ FRDJXODVH DFWLYLW\





RVWHRP\HOLWLV LV DEOH WR UHDFWLYDWH \HDUV DIWHU WKH LQLWLDO
LQIHFWLRQ 7KH ILQDO VWDJH LQ WKH HYROXWLRQ RI D ELRILOP
LQYROYHV WKH GLVSHUVLRQ RI SODQNWRQLF EDFWHULD 7KURXJK






EDFWHULDO FRORQLVDWLRQ ,W LV WULJJHUHGDW WKHVLWHRIEDFWHULDO
LQIHFWLRQ E\ WKH SURGXFWLRQ RI F\WRNLQHV OLNH LQWHUOHXNLQ
,/ ,/ DQG WXPRXU QHFURVLV IDFWRU 71) 7KHVH
F\WRNLQHV UHFUXLW DQG DFWLYDWH SKDJRF\WLF FHOOV VXFK DV
SRO\PRUSKRQXFOHDU301OHXNRF\WHVDQGPDFURSKDJHVWR
SURGXFH EDFWHULRO\WLF IUHH UDGLFDOV 1HXWURSKLOV ZKLFK




RSVRQLVDWLRQ WKH ELQGLQJ RI DQ DQWLERG\ WR D EDFWHULDO
DQWLJHQZKLFKDQFKRUVWKHEDFWHULDWRWKH)FUHFHSWRUVRQ
SKDJRF\WLF FHOOV DQG DFWLYDWHV LQWUDFHOOXODU VLJQDOOLQJ
SDWKZD\V WR SURGXFH IUHH UDGLFDOV OLNH VXSHUR[LGH DQG
QLWURXVR[LGH





FHOOV 7KH VHFRQG FRPSRQHQW LV WKH KXPRUDO UHVSRQVH
LQYROYLQJ WKHSURGXFWLRQRI DQWLERGLHV E\% O\PSKRF\WHV
&HQWUDOO\SRVLWLRQHGZLWKLQWKHDGDSWLYHLPPXQHUHVSRQVH
DUHPDFURSKDJHV ZKLFK SURGXFH 7+ O\PSKRNLQHV ,/
DQG LQWHUIHURQոZKLFK GULYH FHOOPHGLDWHG LPPXQLW\ DV
ZHOO DV 7+ O\PSKRNLQHV ,/ DQG  UHJXODWLQJ WKH




KDYH LGHQWLILHG VHYHUDO EDFWHULDO DQWLJHQLF SURWHLQV LQ
DQWLERG\PHGLDWHG LPPXQLW\ LQ Staphylococcus aureus
ELRILOPEDVHG LQIHFWLRQV LQFOXGLQJ FHOOVXUIDFHDVVRFLDWHG
EHWDODFWDPDVH OLSRSURWHLQ OLSDVH DXWRO\VLQ DQG $%&
WUDQVSRUWHU OLSRSURWHLQ 6RPH RI WKHVH DQWLJHQV DUH
FXUUHQWO\ EHLQJ LQYHVWLJDWHG DV SRVVLEOH WDUJHWV IRU
YDFFLQDWLRQ $QWLDXWRO\VLQPRQRFORQDODQWLERGLHVP$EV
IRU H[DPSOH PD\ KDYH D SURWHFWLYH HIIHFW WKURXJK WKH
LQKLELWLRQRIDGKHVLRQDQGJURZWKRIStaphylococcus sp
Osteo-immunology
&KURQLF RVWHRP\HOLWLV LV FKDUDFWHULVHG E\ RVWHRO\VLV LQ
FRPELQDWLRQZLWK UHSDUDWLYH RVWHRVFOHURVLVZKLFK DLPV WR
FRQILQHWKHLQIODPPDWRU\SURFHVV%DFWHULDOFRPSRQHQWVDQG
WR[LQV KDYH D VWURQJ VWLPXODWRU\ HIIHFW RQ RVWHRFODVWLF
DFWLYLW\ WKURXJK LQGLUHFW 5$1./ DQG RWKHU RVWHR
FODVWRJHQLFIDFWRUVDQGGLUHFWPHFKDQLVPV $VLVWKHFDVH
ZLWK71)EDFWHULDO VXUIDFHDVVRFLDWHGPDWHULDO 6$0FDQ
LQGXFH WKH IRUPDWLRQ RI RVWHRFODVWV IURP PRQRF\WHV
LQGHSHQGHQW RI WKH 5$1./ PHFKDQLVP 2WKHU EDFWHULDO
SURGXFWV VXFK DV OLSRSRO\VDFFKDULGH /36 DQG HQGRWR[LQ
LQGXFH WKH H[SUHVVLRQ RI RVWHRFODVWRJHQLF F\WRNLQHV
LQFOXGLQJ5$1./71) ,/DQG ,/E\RVWHREODVWVDQG
Antibiotics face mechanical and osmotic 
challenges in penetrating a biofilm




EXW DOVR LQKLELW ERQH IRUPDWLRQ WKURXJK LPSDLUPHQW RI
RVWHREODVW GLIIHUHQWLDWLRQ SUROLIHUDWLRQ DFWLYLW\ DQG
VXUYLYDO UHVXOWLQJ LQ QHW UHVRUSWLRQ RI ERQH DW WKH VLWH RI
FKURQLF LQIHFWLRQ$OWKRXJK LW LVZHOO NQRZQ WKDW EDFWHULD
WKDWFDXVHFKURQLFRVWHRP\HOLWLVFDQEHIRXQGLQWUDFHOOXODUO\
ZLWKLQRVWHREODVWV LW LVQRWNQRZQLI WKHVHEDFWHULDKDYHD
GLUHFW LQKLELWRU\ HIIHFW RQ RVWHREODVWV RU LQKLELW ERQH
IRUPDWLRQ WKURXJK PHFKDQLVPV LQYROYLQJ WKH NQRZQ
LQKLELWRU\F\WRNLQHVOLNHVFOHURVWLQ'..RUQRJJLQ
The role of osteoclasts
5HFHSWRU DFWLYDWRU RI QXFOHDU IDFWRU NDSSD% OLJDQG
5$1./LVDSRWHQWDFWLYDWRURIRVWHRFODVWVDQGLVSURGXFHG
E\ ERQH PDUURZ VWURPDO FHOOV XQGHU QRUPDO FRQGLWLRQV
+RZHYHU LQ RVWHRP\HOLWLV FHUWDLQ EDFWHULDO FRPSRQHQWV
VXFKDVOLSRSRO\VDFFKDULGH/36UHVXOWLQWKHSURGXFWLRQRI
5$1./ E\ D YDULHW\ RI FHOOV LQFOXGLQJ DFWLYDWHG 7FHOOV
XOWLPDWHO\ FDXVLQJ DEQRUPDO ERQH ORVV 'HQGULWLF FHOOV
'&VDUHPRQRF\WHGHULYHGDQWLJHQSUHVHQWLQJFHOOVZKLFK
SOD\ DQ LPSRUWDQW UROH LQ ERWK LQQDWH DQG DGDSWLYH
LPPXQLW\ 0LJUDWLQJ GHQGULWLF FHOOV PR'&V WUDQVSRUW
DQWLJHQV IURP WKH VLWH RI LQIHFWLRQ WR O\PSKRLG RUJDQV LQ
RUGHUWRLQLWLDWH7FHOOUHVSRQVHVLQFOXGLQJ&' DFWLYDWLRQ
'HQGULWLFFHOOVDOVRDIIHFWRVWHRFODVWVWKURXJKWKHVWLPXODWLRQ
RI 5$1./ SURGXFWLRQ E\ 7 FHOOV $ VXEVHW RI UHVLGHQW
GHQGULWLFFHOOVFDOOHG7LS'&VSUHVHQWDWWKHVLWHRILQIHFWLRQ
DOVR KDYH VWURQJ DQWLPLFURELDO HIIHFWV WKURXJK WKH




Staphylococcus aureus GLUHFWO\ DFWLYDWHV GHQGULWLF FHOOV
WKURXJK WKH SURGXFWLRQ RI DQ H[RWR[LQ FDOOHG OHXNRFLGLQ
ZKLFK WULJJHUV D 7ROOOLNH UHFHSWRU 7/5 GHSHQGHQW
VLJQDOOLQJ SDWKZD\ Staphylococcus aureus HQWHURWR[LQ %
LQGXFHVPDWXUDWLRQRIGHQGULWLFFHOOVDQGVWLPXODWHVWKHPWR
SURGXFH KLJK OHYHOV RI ,/ $ WKLUGPHFKDQLVPZKHUHE\
Staphylococcus aureus XSUHJXODWHVGHQGULWLFFHOO IXQFWLRQLV
WKURXJKWKHSURGXFWLRQRIWKHSURWHDVHVWDSKRSDLQ%ZKLFK
WKURXJKD FRPSOH[PHFKDQLVP UHVXOWV LQ WKH IRUPDWLRQRI
FKHPHULQ&KHPHULQLQWXUQKDVEHHQVXJJHVWHGWRDFWDVD
SRWHQW FKHPRDWWUDFWDQW WR LPPXQHUHJXODWRU\ GHQGULWLF
FHOOV ,W LV DOVR LQWHUHVWLQJ WR QRWH WKDW XSRQ DFWLYDWLRQ E\
PLFURELDODQWLJHQV&'F GHQGULWLF FHOOV FDQGLIIHUHQWLDWH
LQWR IXQFWLRQDO RVWHRFODVWV LQ WKH SUHVHQFH RIPDFURSKDJH
FRORQ\VWLPXODWLQJ IDFWRU 0&6) DQG 5$1./ H[SUHVVHG
E\DFWLYDWHG&' 7FHOOV





EDFWHULDO SURGXFWV OLNH /36 DQG '1$ WR WKH 7ROOOLNH
UHFHSWRUV7/5DQGRQWKHLUVXUIDFH7KHVHF\WRNLQHV
LQFOXGH DQWLPLFURELDO SHSWLGHV EHWDGHIHQVLQ
FKHPRNLQHV &&/ &&/ &;&/ &;&/
QIODPPDWRU\ F\WRNLQHV ,/ FRVWLPXODWRU\ PROHFXOHV
&'DQG0+&,, 7KHVHFUHWLRQRIWKHVHFKHPRNLQHV
VXJJHVWVWKDWRVWHREODVWVGRQRWRQO\SOD\DQLPSRUWDQWUROH
LQ WKH LQQDWH LPPXQH UHVSRQVH EXW DOVR LQ WKH FHOOXODU
LPPXQH UHVSRQVH &HOOV H[SUHVVLQJ 0+& ,, PROHFXOHV
W\SLFDOO\SUHVHQWH[RJHQRXVDQWLJHQVWR7KHOSHUFHOOV7KH
IDFW WKDW RVWHREODVWV H[SUHVV 0+& ,, PD\ H[SODLQ ZK\
RVWHREODVWVLQWHUQDOLVHEDFWHULDOLNHStaphyloccus aureus7KLV
SURFHVV KDV EHHQ LQYHVWLJDWHG IXUWKHU DQG Staphylococcus 
aureus VLJPD % UHJXORQ KDV EHHQ VKRZQ WR EH WKH NH\






IURP WKH KRVW DQ\ DWWHPSW DW VXUJLFDO HUDGLFDWLRQ RI WKH
LQIHFWLRQPD\ZHOO EH IXWLOH 7KH LPSRUWDQFH RI WKH KRVW·V
DELOLW\ WR ODXQFK DQ HIIHFWLYH LPPXQH UHVSRQVH LV FOHDUO\
LOOXVWUDWHG LQ WKHSULQFLSOHV EHKLQG WKH&LHUQ\ DQG0DGHU
FODVVLILFDWLRQ ZKLFK LQFRUSRUDWHV DVVHVVPHQW RI ORFDO DQG
V\VWHPLF IDFWRUV DIIHFWLQJ WKHKRVWV LPPXQH FRPSHWHQF\
6WXGLHV XVLQJ WKH &LHUQ\ DQG 0DGHU FODVVLILFDWLRQ KDYH




EHWWHU XQGHUVWDQGLQJ LQ WKH UHODWLYHO\ QHZ ILHOG RI RVWHR
LPPXQRORJ\ $V LV WKH FDVH ZLWK EDFWHULDO ELRILOPV RXU
NQRZOHGJHRIWKHKRVW·VUHVSRQVHWRLQIHFWLRQLVDOVRUDSLGO\
H[SDQGLQJ 7KLV NQRZOHGJH FUHDWHV QHZ RSSRUWXQLWLHV LQ
WHUPVRIWKHGHYHORSPHQWRIQRYHOWUHDWPHQWVWUDWHJLHVLQWKH
PDQDJHPHQW RI FKURQLF RVWHRP\HOLWLV DQG SHULSURVWKHWLF
LQIHFWLRQV
The content of this article is the sole work of the author. The 
primary author, LC Marais, has received a research grant from
the South African Orthopaedic Association for research relating
to chronic osteomyelitis..
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&KURQLF RVWHRP\HOLWLV DV D FOLQLFDO HQWLW\ HQFRPSDVVHV D
ZLGH DUUD\ RI FOLQLFDO VFHQDULRV LQFOXGLQJ FKURQLF
KDHPDWRJHQRXVRVWHRP\HOLWLVSRVWWUDXPDWLFRVWHRP\HOLWLV
SHULSURVWKHWLF LQIHFWLRQV DQG FRQWLJXRXV RVWHRP\HOLWLV
2ZLQJ WR WKH KHWHURJHQHRXV QDWXUH RI GLVHDVH WKH ZLGH
YDULHW\RISDWLHQWVDIIHFWHGDQGWKHPXOWLWXGHRIIDFWRUVWKDW
QHHGWREHFRQVLGHUHGGXULQJWKHIRUPXODWLRQRIDWUHDWPHQW
VWUDWHJ\ PRUH WKDQ WHQ FODVVLILFDWLRQ V\VWHPV RI FKURQLF
RVWHRP\HOLWLV KDYHEHHQSXEOLVKHGRYHU WKHSDVW  \HDUV
1RQHRIWKHVHFODVVLILFDWLRQVLVXQLYHUVDOO\DFFHSWHG6RPHRI
WKHV\VWHPVVLPSO\FODVVLI\WKHQDWXUHRIWKHGLVHDVHZKLOH
RWKHUV DWWHPSW WR JXLGH WKH WUHDWLQJ VXUJHRQ RQ FHUWDLQ
DVSHFWV RI WKH PDQDJHPHQW RI FKURQLF RVWHRP\HOLWLV RU
HQDEOH FRPSDULVRQ RI WKH RXWFRPH RI GLIIHUHQW WUHDWPHQW
VWUDWHJLHV
)RUPXODWLQJWKHDSSURSULDWHPDQDJHPHQWVWUDWHJ\DOEHLW
SDOOLDWLYH RU FXUDWLYH LV D FRPSOH[ WDVN 7KH GHFLVLRQ
PDNLQJ SURFHVV UHTXLUHV FRQVLGHUDWLRQ RIPXOWLSOH IDFWRUV
LQFOXGLQJ WKH LPSDLUPHQW UHVXOWLQJ IURP WKH GLVHDVH WKH
SDWLHQW·V IXQFWLRQDO UHTXLUHPHQWV ORFDO DQG V\VWHPLF ULVN
IDFWRUVWKHDQDWRPLFQDWXUHRIWKHGLVHDVHDQGWKHUHDOLVWLF
JRDOVRIWKHUDS\:KHQFRQVLGHULQJWKHULVN²EHQHILWUDWLRRI
DQ\ SURSRVHG PDQDJHPHQW VWUDWHJ\ WKH KRVW·V SK\VLR
ORJLFDO VWDWXV UHPDLQV WKH PDLQ GHWHUPLQDQW RI WKH ULVN
LQYROYHGZLWKDVSHFLILF LQWHUYHQWLRQ7KLV LV LOOXVWUDWHGE\
SUHYLRXV VWXGLHV ZKLFK KDYH LGHQWLILHG WKH SK\VLRORJLFDO
VWDWXV RI WKH KRVW DV WKH PRVW LPSRUWDQW SUHGLFWRU RI
WUHDWPHQW IDLOXUH 7KH VLJQLILFDQW LPSDFW RI LQDGHTXDWH RU
LQFRUUHFW KRVW VWUDWLILFDWLRQ DQG ULVN DVVHVVPHQW LV
HSLWRPLVHG E\ WKH IDFW WKDW IDLOXUH RI D FXUDWLYH OLPE
UHFRQVWUXFWLRQ VWUDWHJ\ RIWHQ UHVXOWV LQ WKH LQHYLWDEOH
DPSXWDWLRQRIWKHLQYROYHGOLPE
Abstract
$VD UHVXOW RI WKHKHWHURJHQHRXVQDWXUHRI FKURQLFRVWHRP\HOLWLV DQG WKH FRPSOH[LW\RIPDQDJHPHQW VWUDWHJ\
IRUPXODWLRQPRUHWKDQWHQFODVVLILFDWLRQV\VWHPVKDYHEHHQSXEOLVKHGRYHUWKHSDVW\HDUV+LVWRULFDOV\VWHPV
XVHG LQ WKHFODVVLILFDWLRQRIFKURQLFRVWHRP\HOLWLV UHPDLQXVHIXO LQ WHUPVRI WKHGHVFULSWLRQRI WKHQDWXUHDQG
RULJLQRI WKHGLVHDVH7KH\IDLOKRZHYHU WRSURYLGHWKHXVHUZLWKVXIILFLHQW LQIRUPDWLRQLQRUGHUWRVHOHFW WKH










7KLV DUWLFOH DLPV WR UHYLHZ WKH DYDLODEOH FODVVLILFDWLRQ
V\VWHPV IRU FKURQLF RVWHRP\HOLWLV DQG KLJKOLJKW VRPH RI
WKHLUVKRUWFRPLQJV)XUWKHUPRUHZHZLOOHYDOXDWHKRZWKH
H[LVWLQJ FODVVLILFDWLRQ V\VWHPV UHODWH WR QHZ DQG HYROYLQJ




WKH V\VWHP GHVFULEHG E\ :DOGYRJHO LQ  7KLV ZDV D
GHVFULSWLYHFODVVLILFDWLRQV\VWHPLQFRUSRUDWLQJWKHVRXUFHRI
WKH LQIHFWLRQ KDHPDWRJHQRXVRUFRQWLJXRXV WKHSUHVHQFH
RI JHQHUDOLVHG YDVFXODU GLVHDVH DQG WKH GXUDWLRQ RI WKH
LQIHFWLRQ DFXWH VXEDFXWH DQG FKURQLF +DHPDWRJHQRXV
FKURQLF RVWHRP\HOLWLV RI ORQJ ERQHV W\SLFDOO\ SUHVHQWV DV
UHFXUUHQFH DW D SUHYLRXV VLWH RI DFXWH KDHPDWRJHQRXV
RVWHRP\HOLWLV ZKLOH KDHPDWRJHQRXV SHULSURVWKHWLF LQIHF
WLRQV LQYROYH VHHGLQJ IURP D GLVWDQW LQIHFWLYH IRFXV
&RQWLJXRXVRVWHRP\HOLWLVPD\EHWKHUHVXOWRIHLWKHUGLUHFW
LQRFXODWLRQ DV LV WKH FDVH LQ SRVWWUDXPDWLF DQG SRVW
RSHUDWLYH LQIHFWLRQV RU DOWHUQDWLYHO\ FRQWLQXRXV VSUHDG
IURP DQ DGMDFHQW VHSWLF IRFXV SUHVVXUH VRUH RU YDVFXODU
XOFHUIRUH[DPSOH$VWKHIUHTXHQF\RIVXUJLFDOLQWHUYHQWLRQ
LQFUHDVHG VR GLG RXU QHHG WR FODVVLI\ FRQWLJXRXV
RVWHRP\HOLWLV.HOO\VXEVHTXHQWO\SXEOLVKHGDQDHWLRORJLFDO








OLQHG VLQXVHV ,Q  :HLODQG et al LQWURGXFHG DQ
DQDWRPLFDO FODVVLILFDWLRQ V\VWHP EDVHG RQ WKH QDWXUH RI
VNHOHWDOLQYROYHPHQWLQRUGHUWRJXLGHWKHXWLOLVDWLRQRIIUHH
WLVVXH WUDQVIHUV GXULQJ WKH UHFRQVWUXFWLRQ SURFHVV 7\SH ,
OHVLRQVZHUH GHILQHG DV VRIW WLVVXH LQIHFWLRQZLWK H[SRVHG
ERQH7\SH,, OHVLRQVZHUHFKDUDFWHULVHGDVFLUFXPIHUHQWLDO
HQGRVWHDO DQG FRUWLFDO LQIHFWLRQ ZKLOH W\SH ,,, OHVLRQV
LQYROYHGHQGRVWHDODQGFRUWLFDOLQIHFWLRQLQWKHSUHVHQFHRID
VHJPHQWDOERQHGHIHFW
$OWKRXJK WKH DERYHPHQWLRQHG FODVVLILFDWLRQ V\VWHPV DUH
XVHIXO LQ WHUPV RI GHVFULELQJ WKH QDWXUH DQGRULJLQ RI WKH
GLVHDVH WKH\ IDLO WR SURYLGH WKH WUHDWLQJ SK\VLFLDQ ZLWK
JXLGDQFH UHJDUGLQJ WKH PDQDJHPHQW RI WKH SDWLHQW 0D\
DQG-XSLWHUDGGUHVVHGWKHVHVKRUWFRPLQJV LQWKURXJK
WKHSXEOLFDWLRQRIWKHLUFODVVLILFDWLRQV\VWHPZKLFKIRFXVHG
RQ WKH VWDWXV RI WKH WLELD DQG LSVLODWHUDO ILEXOD DV D JXLGH
GXULQJ WKH VHOHFWLRQ RI WKH DSSURSULDWH UHFRQVWUXFWLRQ
SURFHGXUHTable I
*RUGRQ et al VLPSOLILHG WKH DSSURDFK WR SRVWLQIHFWLYH




SDWLHQWV IROORZLQJ IUHH PXVFOH WUDQVIHUV 5RPDQz et al
VXEVHTXHQWO\ SURSRVHG D PRUH H[WHQVLYH FODVVLILFDWLRQ
V\VWHPIRUERQHGHIHFWVZKLFKLQFOXGHGGHIHFWVIUHTXHQWO\
VHHQ IROORZLQJ SHULSURVWKHWLF LQIHFWLRQV$FFRUGLQJ WR WKLV
V\VWHP W\SH  OHVLRQV ZHUH GHILQHG DV FDYLWDWRU\ GHIHFWV





3ULRU WR  WKHUH ZDV QR SXEOLVKHG FODVVLILFDWLRQ IRU
LQIHFWLRQV IROORZLQJ RVWHRV\QWKHVLV 5RPDQz et al
UHVSRQGHGWRWKLVRPLVVLRQZLWKWKHSXEOLFDWLRQRIWKH,&6
,QIHFWLRQ&DOOXV6WDELOLW\FODVVLILFDWLRQ$FFRUGLQJWRWKLV
V\VWHP W\SH , LQIHFWLRQ RFFXUV LQ WKH SUHVHQFH RI VWDEOH
LQWHUQDOIL[DWLRQDQGSURJUHVVLRQRIXQLRQRQVHULDO;UD\V
,Q WHUPV RI WKH PDQDJHPHQW RI W\SH , LQIHFWLRQV WKH\
VXJJHVWHGFRQVHUYDWLYHPHDVXUHVXQWLOXQLRQZDVDFKLHYHG
7\SH,,LQIHFWLRQVZHUHGHILQHGDVLQIHFWLRQVLQWKHSUHVHQFH
RI VWDEOH RVWHRV\QWKHVLVZLWKRXW WKH SURJUHVVLRQ RI FDOOXV
7KHDXWKRUVVXJJHVWHGPDQDJLQJWKLVW\SHRILQIHFWLRQZLWK
FRQWURORI WKH LQIHFWLRQDVIRU W\SH,DFFHOHUDWLRQRIERQH
KHDOLQJWKURXJKSK\VLFDOVWLPXODWLRQORZLQWHQVLW\SXOVHG
XOWUDVRXQGIRUH[DPSOHELRORJLFDO IDFWRUVERQHPRUSKR
JHQHWLF SURWHLQ SODWHOHWULFK SODVPD HWF DQG OLPLWHG
VXUJLFDO SURFHGXUHV HJ G\QDPLVDWLRQ RI LQWUDPHGXOODU\
QDLO IL[DWLRQ )RU W\SH ,,, LQIHFWLRQV LQYROYLQJ XQVWDEOH
IL[DWLRQ DQG WKH DEVHQFH RI FDOOXV IRUPDWLRQ UHYLVLRQ
VXUJHU\ZDVUHFRPPHQGHG



















HVSHFLDOO\ LQ WHUPV RI WKH GHVFULSWLRQ RI WKH QDWXUH DQG
RULJLQ RI WKH GLVHDVH:LWK H[FHSWLRQ RI WKH ,&6 FODVVLIL
FDWLRQV\VWHPWKH\IDLOKRZHYHUWRSURYLGHWKHXVHUZLWK
VXIILFLHQW LQIRUPDWLRQ WR IRUPXODWH D WUHDWPHQW VWUDWHJ\
7KH QHHG KDG WKXV DULVHQ WR GHYHORS D PRUH FRPSUH
KHQVLYH FODVVLILFDWLRQ V\VWHPZKLFK LQFRUSRUDWHG VHYHUDO
FULWHULD DQG ZDV DEOH WR JXLGH WKH WUHDWLQJ RUWKRSDHGLF
VXUJHRQWRZDUGVWKHFRUUHFWPDQDJHPHQWVWUDWHJ\
Comprehensive classification systems
&LHUQ\ DQG 0DGHU UHYROXWLRQLVHG RXU DSSURDFK WR
RVWHRP\HOLWLVLQWKURXJKWKHSXEOLFDWLRQRIDFODVVLIL
FDWLRQV\VWHPZKLFKHPSKDVLVHGDPRUHKROLVWLFDSSURDFK
WR WKH SDWLHQW UHFRJQLVLQJ WKH LPSRUWDQFH RI LPPXQH
FRPSHWHQF\ DQG WKH SK\VLRORJLFDO DELOLW\ RI WKH KRVW WR
HIIHFW KHDOLQJ 7KLV V\VWHP LQYROYHG FODVVLILFDWLRQ
DFFRUGLQJ WR WKH KRVW·V SK\VLRORJLFDO VWDWXV DQG WKH
DQDWRPLFQDWXUHRIWKHGLVHDVHTable II
7KH LPSRUWDQFHRI WKHFRQVLGHUDWLRQRI WKHSK\VLRORJLFDO
KRVW VWDWXV RI SDWLHQWV ZLWK RVWHRP\HOLWLV ZDV YDOLGDWHG
WKURXJK&LHUQ\DQG0DGHU·VVWXG\LQYROYLQJSDWLHQWV
7KH KRVW FODVVLILFDWLRQ IDFLOLWDWHG WKH GHFLVLRQPDNLQJ
SURFHVV LQ WHUPVRI RIIHULQJ WKHSDWLHQW WKH DOWHUQDWLYHV RI




,Q RXU RSLQLRQ WKH DQDWRPLFDO VXEVHFWLRQ RI WKH &LHUQ\
DQG0DGHUFODVVLILFDWLRQUHPDLQVDSSOLFDEOHWRGD\DOWKRXJK
WKH GHILQLWLRQ RI WKH VXEW\SHV KDV EHHQ UHILQHG RYHU WKH
\HDUV7\SH,OHVLRQVLPSO\LQIHFWLRQOLPLWHGWRWKHPHGXOOD
ZKLOHW\SH,,OHVLRQVUHIHUWRLQIHFWLRQOLPLWHGWRWKHFRUWH[
7\SH ,,, DQG ,9 LQIHFWLRQV LQYROYH ERWK PHGXOODU\ DQG
FRUWLFDO ERQH ZLWK W\SH ,9 EHLQJ GLIIHUHQWLDWHG E\ WKH
SUHVHQFHRILQVWDELOLW\SULRUWRRUIROORZLQJWKHGHEULGHPHQW
$OWKRXJKLQLWLDOO\LQFOXGHGDVDQDQDWRPLFW\SH,9LQIHFWLRQ
SHULSURVWKHWLF LQIHFWLRQ KDV VXEVHTXHQWO\ DOVR EHHQ
DOORFDWHGLWVRZQFODVVLILFDWLRQV\VWHP
7KH &LHUQ\ DQG 0DGHU FODVVLILFDWLRQ KRZHYHU IDLOHG WR










FODVV $ ZKLOH SDWLHQWV LQ FODVV % KDYH IHZHU WKDQ WKUHH
FRPSURPLVLQJIDFWRUV3DWLHQWVLQFODVV&KDYHWKUHHRUPRUH
FRPSURPLVLQJ IDFWRUV DQGRU RQH RI WKH IROORZLQJ FRQGL
WLRQVDQDEVROXWHQHXWURSKLO FRXQW OHVV WKDQ¬D&'
FRXQWOHVVWKDQLQWUDYHQRXVGUXJDEXVHFKURQLFDFWLYH
LQIHFWLRQRIDQRWKHUVLWHRUG\VSODVLDRUDQHRSODVPRIWKH
LPPXQH V\VWHP 7KLV FODVVLILFDWLRQ V\VWHPZDV KRZHYHU
GHYHORSHG VSHFLILFDOO\ IRU XVH LQ WHUPV RI SODQQLQJ IRU
VHFRQGVWDJHUHYLVLRQDUWKURSODVW\LQSDWLHQWVZLWKLQIHFWLRQ
IROORZLQJ WRWDOKLS UHSODFHPHQW7KH FULWHULD VXJJHVWHGE\
WKHPDUHFRQVHUYDWLYHLQWHUPVRIWKHLUQXPHULFDOYDOXHVDQG
PD\ QRW EH DSSURSULDWH ZKHQ DSSOLHG WR FKURQLF
RVWHRP\HOLWLV LQ WKH 6RXWK$IULFDQ FOLQLFDO VHWWLQJ 6HYHUDO




WKH GHFLVLRQPDNLQJ SURFHVV LQ WKH FDVH RI FKURQLF
RVWHRP\HOLWLV 7KH 0F3KHUVRQ PRGLILFDWLRQ RI WKH &LHUQ\
DQG0DGHUKRVWFODVVLILFDWLRQV\VWHPKDVQHYHUWKHOHVVDOVR






/DXWHQEDFKGHYHORSHGD VWDJLQJ V\VWHP WKDW LQWHJUDWHV
FOLQLFDO ODERUDWRU\ DQG UDGLRORJLFDO IHDWXUHV LQ DQ LQFUH




Cierny and Mader in 1984 published a classification system which
















Factors affecting physiological class























RVWHRP\HOLWLV ZKLFK DUH HDFK GHILQHG E\ FKDUDFWHULVWLF
FOLQLFDODQGODERUDWRU\IHDWXUHVTable IV $VWKHJUDGHVRI
FKURQLF RVWHRP\HOLWLV LQFUHDVH LQ LQWHQVLW\ ZH VHH
SURJUHVVLYH DEQRUPDOLWLHV RI WKH ODERUDWRU\ ILQGLQJV
HVSHFLDOO\ LQ WHUPV RI LURQ VWXGLHV ZKLFK PD\ WKHQ EH
XWLOLVHGLQWKHGLDJQRVLVDQGVWUDWLILFDWLRQRIGLVHDVHVHYHULW\
5HFHQWO\5RPDQzet alDJDLQKLJKOLJKWHGWKHVKRUWFRPLQJV
RI WKH &LHUQ\ DQG 0DGHU KRVW VWUDWLILFDWLRQ V\VWHP DV D
VXEMHFWLYH HYDOXDWLRQ RI WKH KRVW·V SK\VLRORJLFDO DELOLW\ WR
GHDO ZLWK LQIHFWLRQ 7KHLU 6HYHQ,WHP &RPSUHKHQVLYH
&ODVVLILFDWLRQ6\VWHP6,&&6RIERQHDQGMRLQWLQIHFWLRQVIRU
DGXOWV LV EDVHG RQ WKH FOLQLFDO SUHVHQWDWLRQ DHWLRSDWKR
JHQHVLVDQDWRPRSDWKRORJLFDOFKDUDFWHULVWLFVLQFRUSRUDWLQJ
WKH &LHUQ\ DQG 0DGHU DQDWRPLFDO VXEVHFWLRQ IRU ORQJ
ERQHV WKH 0F3KHUVRQ PRGLILFDWLRQ RI KRVW FODVVLILFDWLRQ
IXUWKHUVXEGLYLGHGDFFRUGLQJWRDJHDVOHVVWKDQ\HDUVOHVV
WKDQ  \HDUV DQG PRUH WKDQ  \HDUV RI DJH FDXVDWLYH




FODVVLILFDWLRQ V\VWHPV ,Q FRQWUDVW ZLWK WKH &LHUQ\ DQG
0DGHU FODVVLILFDWLRQ V\VWHP LW ZDV QRW GHVLJQHG WR JXLGH
PDQDJHPHQWEXWLVUDWKHULQWHQGHGIRUGLGDFWLFDQGVFLHQ
WLILF SXUSRVHV LQ RUGHU WR FRPSDUH UHVXOWV IURP GLIIHUHQW
FOLQLFDOWULDOV






KDV EHHQ LGHQWLILHG DV D FUXFLDO IDFWRU GHWHUPLQLQJ WKH
FRXUVHDQGFOLQLFDOPDQLIHVWDWLRQVRI WKHGLVHDVH7KHKRVW
VWDWXVDOVR VHUYHVDV WKHSULPDU\ LQGLFDWRURI WKHSDWLHQW·V
DELOLW\WRHIIHFWKHDOLQJRIERQHDQGVRIWWLVVXHVDVZHOODV
WKHLU DELOLW\ WR ODXQFK DQ HIIHFWLYH LPPXQH UHVSRQVH LQ
FRQMXQFWLRQZLWK DQWLELRWLF WKHUDS\:LWKRXW D FRPSHWHQW
LPPXQH UHVSRQVH IURP WKH KRVW DQ\ DWWHPSW DW VXUJLFDO
HUDGLFDWLRQRIWKHLQIHFWLRQPD\EHIXWLOH
7KHSK\VLRORJLFDOKRVWVWDWXVGRHVQRWRQO\GHWHUPLQHWKH
VXLWDELOLW\ RI D WUHDWPHQW VWUDWHJ\ IRU WKH SDWLHQW EH LW
FXUDWLYHRUSDOOLDWLYHLWDOVRJXLGHVWKHVXUJHRQLQWHUPVRI




VXUJLFDO PDUJLQ 7KH LPSRUWDQFH RI WKH H[WHQW RI
GHEULGHPHQW KDV EHHQ LQYHVWLJDWHG LQ ERWK QRUPDO DQG
FRPSURPLVHG KRVWV &RPSURPLVHG SDWLHQWV %KRVWV
WUHDWHGZLWKPDUJLQDOUHVHFWLRQFOHDUDQFHPDUJLQRIPP
KDG D KLJKHU UDWH RI UHFXUUHQFH WKDQ QRUPDO SDWLHQWV
$KRVWVZKHUHDVDPDUJLQDOUHVHFWLRQPD\EHDFFHSWDEOH
LQQRUPDOKRVWV 7KXVFRPSURPLVHGKRVWVDUHWKHRUHWLFDOO\
EHVW WUHDWHG ZLWK D ZLGH UHVHFWLRQ DQG VXEVHTXHQW OLPE
UHFRQVWUXFWLRQ7KHVHUHFRQVWUXFWLRQSURFHGXUHV LQYROYLQJ
ERQHWUDQVSRUWRUH[WHQVLYHERQHJUDIWVDUHKRZHYHUIUDXJKW
ZLWK GDQJHU DQG IDLOXUH LQYDULDEO\ UHVXOWV LQ WKH
DPSXWDWLRQRIWKHOLPE























Table III: Systemic and local compromising factors according to the



















































Table IV: The Lautenbach classification system14
In our opinion the anatomical sub-section of the 




7KH GHFLVLRQPDNLQJ SURFHVV LV IXUWKHU FRPSOLFDWHG E\
WKDW IDFW WKDW PDQ\ SDWLHQWV VKRXOG QRW UHFHLYH VXUJHU\
EHFDXVH WKH ULVN RI VXUJHU\ PD\ RXWZHLJK WKH EHQHILW




7KXV IXUWKHU FRQVLGHUDWLRQ VKRXOG DOVR EH JLYHQ WR WKH
SDWLHQW·V FXUUHQW IXQFWLRQDO VWDWXV DQG WKH UHDOLVWLFDOO\
DFKLHYDEOHJRDOVRIWUHDWPHQW
,Q 6RXWK $IULFD WKH KLJK SUHYDOHQFH RI LPPXQH





,Q VWDUN FRQWUDVW ZLWK WKH 6RXWK $IULFDQ SXEOLF VHFWRU
ZKHUHDSSUR[LPDWHO\RQHWKLUGRISDWLHQWVDUHFODVVLILHGDV
&KRVWV GHYHORSHG FRXQWULHV GHDO ZLWK D PXFK ORZHU
SHUFHQWDJH,QDUHYLHZRISDWLHQWVVHHQRYHUDSSUR[L




VDIH DSSURSULDWH DQG SDWLHQWVSHFLILF WUHDWPHQW SODQ
8OWLPDWHO\ WKH SDWLHQW·V SK\VLRORJLFDO VWDWXV VKRXOG EH
FRQVLGHUHGDVDFULWLFDOIDFWRUGXULQJWKHIRUPXODWLRQRIWKH
DSSURSULDWHWUHDWPHQWVWUDWHJ\IRUDQLQGLYLGXDO
Shortcomings of existing 
classification systems
7KHILUVWPDMRUVKRUWFRPLQJRIH[LVWLQJFODVVLILFDWLRQV\VWHPV
UHODWHV WR KRVW VWUDWLILFDWLRQ 7KH VWUDWLILFDWLRQ VWUDWHJLHV
FXUUHQWO\ DYDLODEOH KDYH IDLOHG WR GHWHUPLQH VSHFLILF
REMHFWLYH FULWHULD ZKHUHE\ ZKLFK SDWLHQWV ZKR DUH
XQVXLWDEOH IRU D FXUDWLYH PDQDJHPHQW VWUDWHJ\ D W\SH
&KRVW FDQ EH LGHQWLILHG $FFRUGLQJ WR &LHUQ\ W\SH &
KRVWV VKRXOG QRW EH RIIHUHG GHILQLWLYH FDUH EXW UDWKHU
SDOOLDWHGRUVLPSO\WUHDWHGH[SHFWDQWO\ 7KHW\SH&KRVW
DVGHILQHGE\&LHUQ\DQG0DGHULVDSDWLHQWLQZKRPWKH
ULVN RU PRUELGLW\ RI WUHDWPHQW RXWZHLJK WKH EHQHILWV
WKHUHRI RU LQ RWKHU ZRUGV WKH WUHDWPHQW RU UHVXOWV RI
WUHDWPHQWRIFKURQLFRVWHRP\HOLWLVDUHPRUHFRPSURPLVLQJ
WR WKH SDWLHQW WKDQ WKH GLVDELOLW\ FDXVHG E\ WKH GLVHDVH
LWVHOI 7KLV GHILQLWLRQ HQFRPSDVVHV D ODUJH JURXS RI
SDWLHQWV LQFOXGLQJ SDWLHQWVZLWKPLQLPDO GLVDELOLW\ DV D
UHVXOW RI WKH GLVHDVH DV ZHOO DV SDWLHQWV ZKR DUH QRW
VXLWDEOH FDQGLGDWHV IRU FRPSOH[ ERQH DQGRU VRIW WLVVXH
UHFRQVWUXFWLRQ7KHOLPLWDWLRQRIWKLVGHILQLWLRQLVWKHIDFW
WKDWLWLVVXEMHFWLYHZLWKDSRRULQWHUREVHUYHUUHOLDELOLW\
FDVHGHSHQGHQW DQG VXVFHSWLEOH WRZLGHO\ YDU\LQJ LQWHU
SUHWDWLRQGHSHQGLQJRQWKHVXUJHRQ·VH[SHULHQFH
7KHVHFRQGOLPLWDWLRQRIH[LVWLQJFKURQLFRVWHRP\HOLWLV
FODVVLILFDWLRQ V\VWHPV OLHV LQ WKH SDWKRDQDWRPLFDO
FKDUDFWHULVDWLRQRIOHVLRQV7KHUHLVFXUUHQWO\QRXQLYHU
VDOO\ DFFHSWHG FODVVLILFDWLRQ V\VWHP IRU HLWKHU ERQH RU
VRIW WLVVXH GHIHFWV 7KH SUREOHP LV IXUWKHU FRQIRXQGHG
E\ WKH IDFW WKDW WKH PDJQLWXGH RI D ERQH GHIHFW WKDW
VKRXOG EH FRQVLGHUHG DV FULWLFDO DQG WKXV QRW
PDQDJHDEOHZLWKFDQFHOORXVERQHJUDIWUHPDLQVFRQWUR
YHUVLDO 2OGHU FODVVLILFDWLRQV V\VWHPV KDYH IDLOHG WR
NHHS XSZLWK FRQWHPSRUDU\ UHFRQVWUXFWLRQ WHFKQLTXHV
7KH FODVVLILFDWLRQV SURSRVHG E\ 0D\ DQG -XSLWHU IRU
H[DPSOH IDLO WR PHQWLRQ WKH LQGXFHGPHPEUDQH
WHFKQLTXHSRSXODULVHGE\0DVTXHOHW )XUWKHUPRUHWKH
FODVVLILFDWLRQ RI ERQH GHIHFWV YDULHVZLGHO\ LQ WHUPV RI
FXWRIISRLQWVDQGHDFKV\VWHPUHIOHFWVWKHXQLTXHSUHIHU
HQFHVDQGDELOLWLHVRIWKHDXWKRUV:KLOHVRPHVXUJHRQV




WKH &LHUQ\ DQG 0DGHU FODVVLILFDWLRQ·V DQDWRPLFDO VXE
VHFWLRQLVZKHWKHUDVSHFLILFOHVLRQVKRXOGEHJUDGHGDVD
W\SH,,,RUW\SH,9OHVLRQ7KLVGHFLVLRQLVFRPSOLFDWHGE\






































Table V: The Seven-Item Comprehensive Classification System
proposed by Romanò, et al.15
Many patients should not receive surgery because 










UHTXLUH FRPSOH[ UHFRQVWUXFWLRQSURFHGXUHV RU OHDYLQJ
WKHLQIHFWHGERQHEHKLQGDQGDWWHPSWLQJWRVXSSUHVVWKH
LQIHFWLRQ7KHIRUPHUW\SHRIZLGHUHVHFWLRQZLWK¶FOHDU·
PDUJLQV UHVHFWLQJDQ\DYDVFXODUPDWHULDO UHPDLQV WKH
LGHDOEXWLWLVIUHTXHQWO\XQDFKLHYDEOHDVLWPD\LQYROYH
UHVHFWLQJERQHRUVRIWWLVVXHWKDW LVYLWDOWRWKHVXUYLYDO
DQG IXQFWLRQ RI WKH OLPE 2Q WKH RWKHU KDQGPDUJLQDO
UHVHFWLRQVPD\ OHDYH EHKLQG VRIW WLVVXH RU ERQHZKLFK










6\VWHP SURSRVHG E\ 5RPDQz et al LV XVHIXO ZKHQ
GHVFULELQJWKHQDWXUHRIWKHLQIHFWLRQLWLVFRPSOH[DQG
GRHV QRW RIIHU DQ\ JXLGHOLQHV IRU WKH VHOHFWLRQ RI WKH
DSSOLFDEOH WUHDWPHQW VWUDWHJ\ ,Q IDFW WKH DXWKRUV
FRQFOXGH WKDW WKH FODVVLILFDWLRQ V\VWHP VKRXOG ILQG
DSSOLFDWLRQ LQ WKHFRPSDULVRQRIRXWFRPHV UDWKHU WKDQ
EHLQJXVHGDVDJXLGH WRPDQDJHPHQW7KLVSUREOHP LV
QRWXQLTXHWRWKH6,&&6DQGLVDIHDWXUHFRPPRQWRWKH
RWKHU FODVVLILFDWLRQ V\VWHPV 7KH WUHDWPHQW JXLGHOLQHV
RIIHUHGE\&LHUQ\DQG0DGHUKDYHIDLOHGWRNHHSXSZLWK
PRGHUQ WUHQGV LQ WKH VXUJLFDO PDQDJHPHQW RI FKURQLF




DEDQGRQHG7KLVSRLQW LV IXUWKHU LOOXVWUDWHGE\ WKH IDFW
WKDW&LHUQ\DEDQGRQHGWKHRULJLQDOJXLGHOLQHVLQDPRUH
UHFHQWSXEOLFDWLRQ RSWLQJ IRU DPRUHJHQHULF DSSURDFK
WRPDQDJHPHQW
7KH ILQDO OLPLWDWLRQ RI H[LVWLQJ FODVVLILFDWLRQ V\VWHPV
OLHV LQ WKH VWUXFWXUH RI WKH GHFLVLRQPDNLQJ SURFHVV
:KLOHWKHUHDUHWKUHHKRVWW\SHVGHVFULEHGWKHUHDUHRQO\
WZRPDMRUWUHDWPHQWRSWLRQVQDPHO\FXUHRUSDOOLDWLRQ
,Q RUGHU WR DSSHDU ORJLFDO DQG DLG LQ WKH WKHUDSHXWLF
GHFLVLRQPDNLQJSURFHVVHDFKKRVWJURXSVKRXOGLGHDOO\
EHPDWFKHGZLWK LWVRZQXQLTXHPDQDJHPHQWVWUDWHJ\
7KLV ZLOO UHTXLUH UHYLVLRQ RI H[LVWLQJ V\VWHPV DQG WKH
HVWDEOLVKPHQW RI D QHZ XQLILHG FODVVLILFDWLRQ ZKLFK
LQFRUSRUDWHVDOOWKHUHOHYDQWVHOHFWLRQFULWHULDDVZHOODV
DOO FRQWHPSRUDU\ LQWHUYHQWLRQDO VWUDWHJLHV DQG
WHFKQLTXHV
Conclusion
$V VWDWHG E\ &LHUQ\ WKH VHOHFWLRQ RI SDWLHQWPDWFKHG
WUHDWPHQW RSWLRQV IRU H[DPSOH ORZ ULVN WUHDWPHQW LQ
KLJKULVNSDWLHQWVFORVHVWKHJDSLQVXFFHVVIXORXWFRPHV






'HVSLWH WKH GHYHORSPHQW RI FRPSUHKHQVLYH FODVVLIL
FDWLRQ V\VWHPV PDQ\ VKRUWFRPLQJV UHPDLQ ZLWKLQ WKH
GRPDLQ RI GLVHDVH FODVVLILFDWLRQ DQG KRVW VWUDWLILFDWLRQ
7KHIDLOXUHRIH[LVWLQJFODVVLILFDWLRQV\VWHPVWRNHHSSDFH
ZLWK FRQWHPSRUDU\ PDQDJHPHQW SKLORVRSKLHV DQG
PRGHUQ UHFRQVWUXFWLYH WHFKQLTXHV KDV UHVXOWHG LQ WKH
QHHGIRUWKHGHYHORSPHQWRIDQHZFODVVLILFDWLRQV\VWHP
ZKLFK DOORZV LQWHJUDWLRQ RI KRVW IDFWRUV ZLWK WKH
RQFRORJLFDORULHQWHGDSSURDFKZKLFK LVFXUUHQWO\EHLQJ
SRSXODULVHG LQ WKH VXUJLFDO PDQDJHPHQW RI FKURQLF
RVWHRP\HOLWLV
The content of this article is the sole work of the author. The
primary author, LC Marais, has received a research grant
from the South African Orthopaedic Association for research
relating to chronic osteomyelitis.
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The most prominent inadequacy of existing classification 
systems rests in the fact that they fail to guide the user in 
selecting the appropriate treatment strategy from the myriad 
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The management of adult chronic osteomyelitis 
This section provides an overview of the current concepts pertaining to the management of 
chronic osteomyelitis. The lack of evidence-based or consensus guidelines has resulted in the 
fact that the management of adult chronic osteomyelitis is currently mainly based on expert 
opinion.1,2 Although both curative and palliative treatment options are recognized, the way in 
which the appropriate treatment strategy should be selected remains unclear. 
The treatment philosophy involving the application of certain surgical concepts typically 
applied in orthopaedic oncology surgery is explored. This oncologically orientated approach 
reinforces certain important notions, principally the fact that a wide resection is required to 
achieve eradication of the disease.3 A previous report has suggested that the host status may 
be an important consideration when selecting the appropriate surgical margin.4 Simpson et al. 
defined a wide resection as excision of all necrotic and infected bone with ≥5 mm clear 
margin.4 Taking the pathogenesis of the disease into account, specifically the invasive nature 
of the infection, a wide excision may frequently equate to segmental resection. While wide 
resection and limb reconstruction may be advisable to achieve cure in a compromised host; 
the reconstruction procedures required, typically involving bone transport or extensive bone 
grafts, are fraught with danger in the poor host and failure frequently results in the amputation 
of the limb. The issue of wide resection and the maintenance of stability will be discussed 
further in Chapter 7. 
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As is the case with surgical margins, antibiotic therapy in chronic osteomyelitis can also be 
thought of in oncological terms. Directed antibiotic treatment therapy as part of a curative 
treatment strategy can be considered as adjuvant therapy and preoperative antibiotic therapy, 
in cases with abscess formation or cellulitis, can be likened to neo-adjuvant therapy. Chronic 
suppressive antibiotic therapy (CSAT) on the other hand, is used in a similar fashion as 
palliative chemotherapy in the oncology setting. 
Apart from the oncologically orientated approach, several other aspects relating to the 
treatment of adult chronic osteomyelitis will be discussed. Previous classification systems 
failed to consider certain novel therapeutic strategies, for example the Masquelet (induced 
membrane) technique.5,6 The aim of this section was to develop contemporary treatment 
guidelines which incorporate all available options. 
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Introduction
When contemplating open fractures Hippocrates stated that
‘One should especially avoid such cases if one has
reasonable excuse, for the risks are great and rewards are
few’.1 This statement still rings true today for chronic
osteomyelitis. Prior to the implementation of contemporary
classifications systems poor results were universally
reported in the management of chronic osteomyelitis. 
The Mayo Clinic, for example, reported a failure rate of
20% and this figure deteriorated to failure in over 60% of
patients in the presence of mixed aerobic and anaerobic
infections.2
Abstract
To date, no evidence-based guidelines for the treatment of chronic osteomyelitis exist. Owing to certain similarities,
treatment philosophies applicable to musculoskeletal tumour surgery may be applied in the management of chronic
osteomyelitis. This novel approach not only reinforces certain important treatment principles, but may also allow for
improved patient selection as surgical margins may be customised according to relevant host factors. When distilled
to its most elementary level, management is based on a choice between either a palliative or curative approach.
Unfortunately there are currently no objective criteria to guide selection of the most appropriate treatment pathway. 
The pre-operative diagnostic work-up should be tailored according to the relevant objective, albeit confirming the
clinical suspicion of the presence of infection, host stratification, anatomical disease classification, pre-operative
planning or post-operative follow-up. MRI and PET-CT are emerging as the imaging modalities of choice.
Interleukin-6, in combination with CRP, has been shown to have excellent sensitivity in the diagnosis of 
implant-associated infection. Molecular methods are growing rapidly as the method of choice in pathogen detection.
Chronic osteomyelitis, as is the case with musculoskeletal tumours, can only be eradicated through complete
resection of all infected bone. Chemotherapy, in the form of antibiotics, only plays an adjuvant role. Dead space
management is essential following debridement, and the appropriate strategy should be selected according to the
anatomical nature of the disease. Provision of adequate bony stability is crucial as it promotes revascularisation and
maximisation of the host’s immune response. Although there is currently a variety of fixation options available,
external fixation is generally preferred. 
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Chronic osteomyelitis can only be eradicated through 
complete resection of all infected bone
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The poor outcome of treatment in chronic bone infections
has inspired many changes in our management strategy
over the past few decades. The 1970s can be seen as the era
of secondary healing. During this period sequential
debridement, healing by secondary intention and long-term
antibiotic treatment were the order of the day.
Reconstruction options were often limited to open sky
techniques (Papineau grafting) or bypass grafting. As a
result of these limitations the extent of surgical debridement
was restricted and residual fibrotic and ischaemic tissue was
often left behind, impairing the host’s ability to launch an
effective defence against bacterial persistence. In the 1980s
wound revitalisation, involving thorough wound
debridement with excision of all ischaemic tissue, became
the mainstay of treatment. In conjunction with systemic and
local antibiotic therapy, wound revitalisation allowed early
closure of wounds following the debridement.3 The era of
revascularisation followed as a result of this new-found
ability. In the 1990s free tissue transfer involving microvas-
cular anastomosis became an integral part of the post-
infective reconstruction process. The advances in soft tissue
management culminated in the creation of a wound bed that
was able to withstand the metabolic demands of more
complex limb reconstruction procedures. In the past two
decades, the potential for skeletal reconstruction has reached
new heights. Salvage protocols for peri-prosthetic infection,
incorporating staged endo-prosthetic replacement, have
grown in popularity. The propagation of the science of
distraction osteogenesis and Ilizarov techniques outside of
Russia has allowed surgeons the opportunity to reconstruct
much larger bone defects than before. Most recently the
induced membrane technique, popularised by Masquelet,
has emerged as a useful adjunct in the management of large
bone defects following debridement.
In Part I of this two-part series we will discuss the
management strategies currently available for the
management of chronic osteomyelitis. Certain novel
concepts, key to the decision-making process, will also be
introduced. The different diagnostic modalities, which may
be employed in the conformation of the presence of infection
or during the pre-operative workup of the patient, will also
be explored. Finally we will discuss the surgical
management strategies that may be implemented during the
first stage of treatment, with specific reference to
debridement techniques, pathogen detection, dead space
management and skeletal stabilisation. In Part II of this
series on the management of chronic osteomyelitis, which
will be published in the next issue of this journal, we will
review antibiotic therapy, as well as soft tissue and skeletal
reconstruction following debridement.
Management strategies
To date, no evidence-based guidelines exist in terms of the
treatment of chronic osteomyelitis.4 When distilled to its
most elementary level, management is based on a choice
between either a palliative or curative approach.
Management strategies, aimed at eradication of infection
and limb reconstruction, incorporate a wide array of surgical
procedures and techniques in terms of debridement, dead
space management, soft tissue cover and skeletal recon-
struction. While curative management strategies usually
involve multiple surgical procedures, palliative treatment
strategies, on the other hand, are much less invasive and
typically involve the use of chronic suppressive antibiotic
therapy. Thus the most important decision a surgeon faces is
whether to embark on either a curative or a palliative
treatment strategy. 
This decision regarding cure or palliation requires consid-
eration of several factors, foremost of which is the host’s
physiological status. As described by Cierny, a C-host
should be palliated, whereas A- and B-hosts may be
considered for a curative treatment protocol. The main risk
involved in certain curative treatment strategies, is the fact
that treatment failure may result in unplanned amputation
of the limb. If, for example, wide resection and limb recon-
struction through bone transport is embarked upon in a
patient who is unable to cope with the physical or physio-
logical demands of the process, failure of the reconstruction
process may result in amputation. To justify the morbidity
and risk of limb salvage, the expected outcome must offer
distinct advantages over an amputation or palliation alone.
If treatment aimed at cure is contraindicated or excessive, as
a result of the risk it entails, the patient should be classified
as a C-host and offered palliation (incision and drainage,
oral antibiotics, ambulatory aides, and pain medication).
Amputation may be indicated when limb salvage and palli-
ation are neither safe nor feasible.5 The main problem we
currently face, however, is the absence of objective criteria
according to which a C-host should be defined.
Owing to various similarities, principle among which is
the high recurrence rate following incomplete excision,
certain treatment philosophies applicable to musculoskeletal
tumour surgery may also be applied when formulating a
treatment plan for chronic osteomyelitis. Excision margins,
for example, may be thought of in oncological terms with a
simple sequestrectomy representing an intralesional
excision, direct or indirect unroofing a marginal excision,
and finally a complete resection can be seen as a wide
excision. Similarly antibiotic therapy can be thought of as
chemotherapy which may be instituted in a neo-adjuvant,
adjuvant and palliative setting. This novel approach to
chronic osteomyelitis not only reinforces certain important
treatment principles, but may also allow for improved
patient selection as surgical margins may be customised
according to relevant host factors. 
Pre-operative considerations
Clinical evaluation
Patient evaluation should include a meticulous history
taking and careful examination. 
Information should be gathered regarding the main
complaint, associated problems, medical history, previous
surgical history and prior therapeutic interventions.
Examination should include a systemic evaluation as well
as a thorough assessment of the local pathology, skeletal
stability, the condition of the soft tissues, vascularity and
neurological status.
Imaging
Imaging modalities should be tailored to the relevant
objective, albeit confirming the clinical suspicion of the
presence of infection, anatomical disease classification,
pre-operative planning or post-operative follow-up. 
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Ultrasonic waves do not cross cortical bone but ultra-
sound is still useful in the assessment of the presence of
periosteal reaction or purulent collections. Ultrasound may
also be utilised as a guide during deep aspiration of fluid
collections for culture and sensitivity. X-rays and CT
scanning are useful in localising sequestra or cloacae and
also aid in the assessment of skeletal integrity and stability
(Figure 1). 
MRI has evolved as the modality of choice, especially in
light of the modern oncologically oriented approach. It
provides the most accurate information on extent of disease
in bone and soft tissue and is therefore especially useful
when planning a marginal or wide resection6 (Figure 2).
Positron emission tomography (PET) scanning has also
gained popularity and has surpassed MRI as the most
sensitive and specific imaging modality to diagnose the
presence of infection.7 It has also been shown that 18F-FDG
PET/CT is a highly sensitive and specific method in the
evaluation of chronic post-traumatic infection. PET/CT
allows precise anatomical localisation and characteri-
sation, demonstrating the extent of involvement with a
high degree of accuracy.8
Laboratory investigations
As is the case with imaging modalities, laboratory investi-
gations may be used in several contexts. In all patients a
comprehensive haematological and biochemical profile,
including a full blood count, renal and liver function tests,
as well as an electrolyte and nutritional profile is required
in order to stratify the host’s physiological status. In
addition, supplementary tests may be required to
ascertain the degree of systemic compromise as a result of
certain specific disorders. Examples include HbA1C
assessment in the case of diabetes mellitus, creatinine
clearance in patients with chronic renal failure, and CD4
counts and viral loads in HIV-infected individuals.
The second capacity in which laboratory studies can be
utilised is as a diagnostic tool in the confirmation of the
presence of sepsis. In this respect Lautenbach has shown
that iron studies are particularly useful with an increased
ferritin:iron ratio (in excess of 7), a decrease in iron
saturation, as well as a decrease in mean cell volume and
mean cell haemoglobin, all pointing to the presence of
underlying infection.9 Routine infection markers,
including the leukocyte count (WBC), erythrocyte
sedimentation rate (ESR), and C-reactive protein level
(CRP) may be used in both the diagnosis of the presence of
infection as well as the follow-up of the patient. It should
however be kept in mind that the WBC and ESR may be
normal in extensive non-inflamed, and localised lesions
(grade 6 and 7 infections according to the Lautenbach
classification system). Pro-calcitonin (PCT) is currently
routinely used in the diagnosis of the presence of severe
infections in critically ill patients.10 Pro-calcitonin however
has a limited role in the diagnosis of the presence of
osteoarticular infection, with a sensitivity of only 16.6% in
osteomyelitis and 33% in peri-prosthetic infections.11,12 In
addition PCT does not appear to be superior to CRP in the
post-operative follow-up of patients.13 In contrast to pro-
calcitonin, the combination of abnormal CRP and
inteleukin-6 has been shown to be 100% sensitive in the
diagnosis of deep infection in the presence of an implant.10
On the other hand tumour necrosis factor and interleukin-
8 have been shown to be elevated in acute, but not in
chronic post-traumatic osteomyelitis.14 These pro-inflam-
matory cytokines have unfortunately not been studied in
the setting of chronic haematogenous osteomyelitis.
Figure 1. X-ray and CT scan images illustrating cortical
sequestration as a result of chronic haematogenous
osteomyelitis
Positron emission tomography (PET) scanning has also gained
popularity and has surpassed MRI as the most sensitive and specific
imaging modality to diagnose the presence of infection
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Host stratification and optimisation
Following the confirmation of the presence of infection and
determination of the severity of the disease, attention should
shift towards accurate anatomical and physiological classifi-
cation. Numerous classification systems have been
described. The Cierny and Mader system remains the most
popular classification system in use today. The most
important decision is to embark on either a curative or
palliative treatment strategy. Once a curative management
option is selected emphasis should be placed on host optimi-
sation, and modifiable risk factors should be addressed.
Reversal of these risk factors will improve the outcomes in
B-hosts to more closely resemble the results seen in A-
hosts.15 Cessation of smoking, tight glycaemic control and
dietary supplementation, for example, take precedence over
any surgical intervention. 
Pathogen identification
Cierny has previously recommended that attempts be made
to identify the pathogen prior to the first formal surgical
debridement through biopsy of deep granulation tissue.16
This view is not uniformly held and not routinely imple-
mented. In cases without significant local or systemic septic
complications, pathogen detection may be delayed to after
the primary debridement procedure. In certain scenarios
pre-operative (‘neo-adjuvant’) antibiotics may be
mandatory, for example in patients with significant local
(cellulitis in the region of the incision) or systemic
compromise (systemic sepsis or septic shock). In such cases
pre-operative identification of the causative organism is
essential and samples for microscopy, culture and sensitivity
(MCS) should be obtained either through open biopsy or
deep aspiration under ultrasound guidance, prior to defin-
itive surgery. 
Contrary to popular belief swab culture from a sinus may
offer some diagnostic benefit. Firstly, the identification of
methicillin-resistant S. aureus (MRSA) or vancomycin-
resistant enterococcus necessitates the implementation of
stringent infection control measures during hospitalisation.
Secondly, isolation of S. aureus from a superficial culture has
a high degree of correlation with deep cultures.17
In cases without significant local or systemic septic compli-




As is the case with musculoskeletal tumours, eradication of
chronic osteomyelitis can only be achieved through
adequate resection. Chemotherapy only plays an adjuvant
role. Unless a palliative treatment pathway has been chosen,
all necrotic or ischaemic tissues should be excised.16 All
foreign bodies and surgical implants need to be removed,
with the exception of early infection following osteosyn-
thesis where union is expected to occur. Soft tissues, and
especially scar tissue, should be resected to a supple, well-
perfused margin.18 In terms of the bony debridement several
techniques are currently available including simple
sequestrectomy, intra-medullary reaming (indirect
unroofing), tangential excision (direct unroofing), segmental
resection and amputation. Despite the fact that several
techniques have been described in order to determine the
viability of bone, ‘point-of-care testing’ (POCT) remains the
most trustworthy tool.19 This technique involves intra-
operative assessment of bone colour, bone sound, bone
texture, as well as the quality of the cancellous bone and
surrounding soft tissues in order to distinguish vital bone
from vital-affected bone or devitalised bone. Devitalised
bone should be excised to the point where punctate
bleeding, also known as the ‘paprika sign’, is noted.20
Schmidt et al. illustrated that osteitis can only truly be
eradicated through complete resection of all infected bone,
and that remaining infected or devitalised bone segments
may act as a source for persistent infection or result in late
reactivation. On the other hand, the authors pointed out that
affected bone may recover when it is surrounded by vital,
healthy soft tissue.21 When contemplating the extent of the
debridement the anatomic nature of the disease, the physio-
logical condition of the host and the proposed skeletal recon-
struction technique should be considered. Compromised
hosts, for example, are theoretically best treated with a wide
resection of all infected tissues and subsequent limb recon-
struction.22 But herein resides one of the main problems a
surgeon faces when dealing with a compromised host. Wide
resection and limb reconstruction is advised to achieve cure,
but the reconstruction procedures required, typically
involving bone transport or extensive bone grafts, are
fraught with danger in the poor host and failure frequently
results in the amputation of the limb.
Pathogen detection
Routine microscopy, culture and sensitivity (MCS) of tissue,
bone and exudates taken under aseptic condition in the
absence of antibiotic therapy in the preceding ten days, still
serves as the primary diagnostic modality in order to
confirm the presence of infection.23 Multiple samples should
be acquired early in the procedure from fluid collections,
soft tissue, bone and foreign materials or sequestra. 
Figure 2. X-ray and MRI images indicating cancellous sequestration
in the metaphysis of the distal femur
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This so-called ‘spacer effect’ has proven very useful in the
reconstruction of bone defects, where the resulting cylinder
forms a stable receptacle for bone graft and also serve as a
framework through which a bone segment may be trans-
ported.
Skeletal stabilisation
It is has been shown that skeletal stability results in a statis-
tically significant reduction in the incidence of infection
following open fractures.38 This principle also applies to
skeletal reconstruction following debridement of infected
bone. In an animal model it was found that the union of an
infected fracture is directly related to the degree of bony
stability.39 The theory is that stability promotes revasculari-
sation, resulting in enhanced perfusion and maximisation of
the host’s immune response.40
A variety of fixation options is currently available,
although external fixation is generally preferred.
Intramedullary PMMA nails do provide some stability, but
cannot achieve the level of stability provided by external
fixation. Curtis and colleagues found, in an experimental
model, that infected osteotomies stabilised with external
fixation had fewer and less severe infections than those
stabilised with either a reamed or unreamed intra-
medullary nail.41 Circular external fixators have gained
much popularity in the field of post-infective reconstruction
as a result of their modularity, minimally invasive nature
and ability to effect bone transport and deformity correction.
The attributes of fine wire fixators, in particular, are
commonly used in the setting of septic non-unions and post-
infective skeletal reconstruction. When dealing with a bone
transport docking site, for example, the aim is to create the
optimal biological milieu through the use of osteo-inductive
materials in combination with the ideal mechanical
environment. External fixation cannot achieve the level of
stability required for primary bone healing, and union is
therefore generally achieved through enchondral ossifi-
cation. As predicted by the inter-fragmentary strain theory
this can only be achieved under conditions resulting in inter-
fragmentary strain of 2 to 10%.42 This mechanical
environment can reliably be created through the use of fine
wire circular fixators. Tensioned fine wires exhibit increased
axial stiffness with higher loads.43 This non-linear, load-
dependent axial stiffness is similar to the viscoelastic
properties of tendons and ligaments. As result of these
biomechanical attributes fine wire circular external fixators
can be described as the only true form of true biological
fixation.44
Conclusion
Many questions regarding the management of chronic
osteomyelitis remain unanswered. The wide variety of
treatment options currently available, combined with the
advances in our surgical reconstruction abilities, makes
disease classification and accurate host stratification now
more important than ever. 
A dilemma commonly encountered is whether to embark on
a palliative or curative treatment pathway. Although
existing classification systems do offer some guidelines, the
lack of objective selection criteria makes the decision a
subjective one. The critical significance of correct patient
selection is epitomised by the fact that failure of a curative
(limb reconstruction) strategy invariably results in
amputation of the involved limb. 
Surgical debridement offers definite advantages in terms
of achieving eradication of infection. However, not all cases
require surgical intervention in order to achieve quiescence
and certain patients may be successfully treated with antibi-
otics alone. In the second part of this series on the
management of chronic osteomyelitis, the principles of
antibiotic therapy, as well as the current concepts in post-
debridement reconstruction, will be explored. 
The content of this article is the sole work of the authors. The
primary author has received a research grant from the South
African Orthopaedic Association for research relating to chronic
osteomyelitis.
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Abstract
Over the past few decades considerable progress has been made in terms of our ability to reconstruct post-
infective soft tissue and bone defects. Soft tissue reconstruction is not always required and it is frequently
possible to achieve a tension-free closure of well-perfused tissue following debridement. It is now generally
accepted that primary closure of the wound, be it by direct suturing or tissue transfer, may be performed at the
same sitting as the debridement. In cases were debridement has resulted in tissue loss, muscle or musculocu-
taneous flaps appear to be superior to random-pattern flaps in achieving resolution of infection. The
management of bone defects is dependent on several factors including the host’s physiological status, the size
of the defect, duration of the defect, quality of the surrounding soft tissue, the presence of deformity, joint
contracture/instability or limb length discrepancy, as well as the experience of the surgeon. 
Surgery remains the mainstay of treatment when a curative treatment strategy is selected. As is the case with
chemotherapy for bone tumours, antibiotic therapy fulfils an adjuvant role in curative management strategies.
The choice of antibiotic, in this setting, remains a very difficult one and there are many problems with the inter-
pretation of ‘cure rate’ data. The controversy surrounding the optimal duration and route of antibiotic therapy
has not been resolved. The second role of antibiotics in the management of chronic osteomyelitis is disease
suppression as part of a palliative treatment strategy. Further studies are required to clarify which patients may
successfully be treated with antibiotics alone.
Key words: osteomyelitis, chronic, management, review
Part I of this article – Diagnostic work-up and surgical principles – was published in the previous
issue of the South African Orthopaedic Journal, Winter 2014, vol 13, no 2
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Introduction
The complex and heterogeneous nature of chronic
osteomyelitis necessitates a multi-disciplinary approach,
involving experts in the field of orthopaedic tumour,
infection and limb reconstruction surgery, plastic surgery,
microbiology, nursing, physiotherapy and psychology.
Numerous surgical techniques and adjuvant therapies
have been developed during the past three decades in
order to deal with the wide spectrum of pathology that
falls under the heading of chronic osteomyelitis. Despite
these developments, the outcome of current treatment
protocols remains unsatisfactory, with failure of therapy
reported in up to 20% of cases.1 
The preceding article in this series aimed to elucidate
current concepts in the diagnostic work-up and surgical
management of chronic osteomyelitis. In this paper post-
infective soft tissue and skeletal reconstruction, as well as
the principles of antibiotic therapy, will be addressed.
There are several controversial issues related to these
subjects. The optimal choice for soft tissue cover following
debridement, for example, remains controversial.
Although several techniques have been described to deal
with bone defects, a comprehensive contemporary
strategy has not yet been described. In terms of antibiotic
therapy, clear evidence-based guidelines are also lacking,
especially in terms of the selection of the appropriate
antibiotic agents, the optimal duration of treatment and
the ideal route of administration. 
Post-debridement reconstruction
Soft tissue reconstruction
In many cases it is possible to achieve a tension-free
closure of well-perfused tissue following debridement.
Unfortunately the excision of ischaemic tissue and sinuses
frequently result in a soft tissue defect. It is now generally
accepted that primary closure of the wound, be it by direct
suturing or tissue transfer, may be performed at the same
sitting as the debridement.2,3 Cierny, however, emphasises
the importance of systemic and local antibiotics, as well as
a double setup in case of a single stage procedure. This
involves re-scrubbing of all staff members, repeat prepa-
ration and draping of the patient, as well as the use of new
instruments for the reconstructive part of the procedure.4
Delayed primary closures may still be required in certain
cases where, for example, a second look at the viability of
remaining tissue is required, soft tissues are not amenable
to closure due to swelling or induration, or where a second
team is required to perform a complex free flap. 
In the past post-debridement soft tissue defects were
often left to heal by secondary intention or dealt with
through the use of open-sky techniques like Papineau
bone grafting. These methods have subsequently fallen
out of favour, and authors like Ger have promoted the
principle of muscle flap coverage in order to achieve
improved cure rates.5,6 This approach was justified
through animal studies which showed that muscle or
musculocutaneous flaps were superior to random-pattern
flaps (i.e., local flaps) in achieving resolution of infection.7
In an experimental model, Feng and colleagues were able
to explain this phenomenon by showing increased blood
flow and more consistent leukocyte mobilisation in
musculocutaneous flaps when compared to random flaps.
In addition, the oxygen tension in soft tissue defects
covered by muscle flaps was shown to be higher than
those covered through random-pattern flaps. The advan-
tages of muscle flaps have also been illustrated in the
clinical setting, although a recent review still questioned
the clinical validity of the theoretical advances of muscle
flaps in the setting of infection.8,9
With the advances in microsurgical techniques in the
recent past, free tissue transfer has become more acces-
sible. The success achieved with free flaps in the
management of open fractures has prompted utilisation of
these techniques in the management of chronic
osteomyelitis. The excellent results, in terms of bony union
and eradication of infection, with free muscle transfer in
chronic osteomyelitis, have also been attributed to the
dramatic increase in the local blood supply.10 In addition,
performing a debridement and free flap in a single sitting
has been shown to be reliable in achieving cure.3 Recently,
perforator free flaps have gained much popularity in the
management of open fracture and have been suggested to
be superior in the management of tibial osteomyelitis.11
Although free anterolateral thigh fasciocutaneous flaps
have been shown to be effective in the management of
open tibia fractures, it is technically challenging and free
muscle- or musculocutaneous flaps are still considered the
method of choice in coverage of lower leg defects.12
Several other salvage techniques have emerged in the
recent past. Negative pressure dressing has been
employed successfully in the management of many soft
tissue defects. It has, however, a limited role in the
management of chronic osteomyelitis as it results in the
formation of dense and poorly vascularised scar tissue.
The application of vacuum dressings to draining sinuses
in particular is discouraged as it significantly complicates
subsequent surgery.4 Vacuum dressing may occasionally
be considered in severely compromised hosts where tissue
transfer is deemed impossible. More recently negative
pressure wound therapy combined with the instillation of
solution in the local area (VAC instil therapy) has been
proposed as a viable alternative in the management of
osteomyelitis-associated soft tissue defects.13 This form of
therapy is attractive as it offers the theoretical advantages
of both the Lautenbach technique and negative pressure
wound therapy. As a last resort, in certain cases where the
local soft tissue condition does not permit flap coverage,
open skeletal transport (in accordance with Ilizarov
principles) may be considered. 
Skeletal reconstruction
Cierny and Mader type I, II and III lesions are, per
definition, stable and generally do not require recon-
struction of the defect left by the debridement. Type IV
lesions, on the other hand, are characterised by instability
and routinely require stabilisation and reconstruction of
osseous defects resulting from the debridement. Existing
classification systems for post-osteomyelitis bone defects,
including those suggested by May and Gordon, have
failed to keep up with the modern trends in limb recon-
struction surgery and have therefore lost some of their
value.14,15
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Acute shortening, with primary docking of the bone
ends, of up to 4 cm has been advocated for post-traumatic
bone loss.16 Unfortunately the soft tissue scarring
associated with chronic osteomyelitis rarely permits acute
shortening beyond 2 cm. Not only does acute shortening
in the presence of significant scar tissue present technical
difficulties with wound closure, it also carries a particular
risk of vascular compromise as a result of kinking of blood
vessels which are immobilised by rigid soft tissues. Acute
shortening of 1–2 cm can, however, be used as part of a
combined strategy, which may include the induced
membrane technique along with bone grafting or bone
transport.
The size of a segmental bone defect which should be
considered critical, and thus not suitable for autologous
cancellous bone grafting, remains controversial.
Traditionally approximately 4 cm has been recommended as
the cut-off point.17,18 The first problem with cancellous bone
grafting is its dependence on the surrounding soft tissues for
nourishment. Large grafts may undergo central necrosis in
the absence of an excellent soft tissue envelope (bone bed).19
Secondly the regenerated segment is often weak and prone
to fracture as a result of partial graft resorption.20 As a result,
Tiemann et al. recommended 2 cm as the maximum size of a
segmental diaphyseal tibial defect that can be managed with
autologous cancellous grafting.19
The advent of induced membrane techniques has,
however, increased the potential for the use of
cancellous bone graft in much larger defects. Masquelet
reported the successful use of this technique in 35 cases,
with defects ranging from 4–25  cm.21 Others have been
able to reproduce these results. 
Unfortunately the soft tissue scarring associated with chronic
osteomyelitis rarely permits acute shortening beyond 2 cm
Figure 1. Post-traumatic, contiguous chronic osteomyelitis of the tibia. Following marginal resection of the necrotic bone
the resulting bone defect was treated with cancellous bone graft into an induced membrane (classic Masquelet
technique).21
The advent of induced
membrane techniques has
increased the potential for
the use of cancellous bone
graft in much larger defects
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Stafford reported a 90% union rate of defects ranging from
1–25 cm (average 5.8 cm) with the use of reamer-irrigation-
aspiration graft.22 Although the induced membrane
technique offers several theoretical and practical advan-
tages, caution should be applied in the use of cancellous
bone graft in tibial defects exceeding 4 cm, especially in the
absence of periosteal new bone formation (Figure 1).19
Distraction osteogenesis, in accordance with the Ilizarov
method, remains the gold standard in the management of
post-debridement bone defects of 4 cm or more.16,23 This may
take the form of acute shortening with subsequent length-
ening or, more commonly, bone transport into the defect.
Distraction osteogenesis offers several advantages in the
management of chronic osteomyelitis, including the increase
of regional blood flow for a period of up to 17 weeks
following the corticotomy.24 Large defects can be dealt with
through simultaneous multifocal transport, sequential
transport or cable-transport techniques. The upper limit of
the size of defects which may be dealt with through
distraction osteogenesis is, however, highly dependent on
the surgeon’s experience with the technique (Figure 2).
Circular fixation and bone transport is associated with its
own subset of complications and a second procedure
involving cancellous grafting of the docking site (formal
docking) is generally recommended.25 Following a
comparative study, El-Gammal and colleagues suggested
that defects smaller than 12 cm should be reconstructed
with Ilizarov bone transport while free vascularised fibula
grafts performed better in defects larger than 12 cm.26
Although vascularised fibula grafts, fibula-pro-tibia
(fibula centralisation) or fibula bypass grafting remain
options for defects in excess of 12 cm these procedures
involve donor site morbidity and is often complicated by
non-union or fracture of the graft during the period of
hypertrophy (Figure 3).27
A combination of techniques is commonly used.
Ultimately the management of bone defects is dependent
on several factors including the host’s physiological status,
the size of the defect, duration of the defect (i.e. acute or
chronic), quality of the surrounding soft tissue, the
presence of deformity, joint contracture/instability or limb
length discrepancy, as well as the experience of the
surgeon. 
Antibiotic therapy
It is important to note that surgery remains the mainstay of
treatment when a curative treatment strategy is selected. As
is the case with chemotherapy for bone tumours, antibiotics
fulfil an adjuvant role in curative management strategies.
Curative surgery should ideally involve a wide resection
with clear margins. This goal is however frequently
unachievable as it may result in unreconstructable loss of
bone that is vital to the survival and function of the limb.
Marginal resection may, on the other hand, leave behind
colonised bone or soft tissue that may serve as a nidus for
recurrent infection.28 Even in wide resections the remaining
bone and soft tissue bed should also be considered contam-
inated. Antibiotics are, therefore, used in wide and marginal
resections (curative surgical strategies) in an attempt to
sterilise the remaining bone and soft tissues. In the curative
setting empirical adjuvant antibiotics are typically started
immediately following the debridement, and the regimen is
modified once the culture and sensitivity results become
available. 
The first role of antibiotics in the management of chronic
osteomyelitis, is adjuvant therapy as part of a curative
treatment strategy. The choice of antibiotic, in this setting,
remains a very difficult one and there are many problems
with the interpretation of ‘cure rate’ data. Firstly there are
no standardised definitions for cure or failure of treatment
and no universally accepted host stratification system. In
addition, many of the historical studies evaluated the
efficacy of antibiotics in the absence of surgical debridement
or surgical implants. Studies often include a heterogeneous
group of patients in terms of their physiological status, the
aetiological source of the infection and the anatomical/
pathological nature of the disease. Finally, in vivo effect does
not always mirror the high degree of efficacy predicted by
in vitro investigations. Empirical antibiotics should be
selected on the basis of the aetiology of the infection as well
as local pathogen profiles. β-lactams and vancomycin are
the most commonly used antimicrobials in the medical
management of osteomyelitis.29
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Figure 2.  Contiguous chronic osteomyelitis following a failed open
reduction of a tibial shaft fracture. Wide resection of the necrotic
bone segments was performed and an antibiotic-impregnated PMMA
spacer inserted. Following removal of the spacer the resulting 8 cm
bone defect was addressed with distraction osteogenesis. Union was
achieved after a formal docking procedure.
Circular fixation and bone transport is associated with its 
own subset of complications and a second procedure involving
cancellous grafting of the docking site is generally recommended
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In terms of contiguous infections, The Bone Infection Unit
in the United Kingdom recommends empirical parenteral
vancomycin and meropenem.2 Although this protocol
covers a broad range of pathogens there are some
potential concerns. Vancomycin offers excellent activity
against MRSA and ampicillin-resistant enterococci.
Unfortunately it has several drawbacks including poor
bone penetration, increased minimal inhibitory concentra-
tions among many S. aureus strains and has been shown to
have increased recurrence rate when compared with
cefazolin or ceftriaxone.30,31 β-lactam antibiotics
(penicillins, cephalosporins and carbapenems) exhibit
poor bone penetration, with levels reaching only approxi-
mately 5–20% of serum concentrations. Fortunately serum
levels of parenteral β-lactams are so high that the resulting
bone levels most likely exceed the necessary minimum
inhibitory concentration (MIC).32 Cefepime appears to be a
reasonable alternative to meropenem, offering good
activity against Gram-negative organisms, and it has been
shown to have excellent bone penetration, with bone
concentration reaching 97–100% of serum levels.33
In terms of the route of administration, oral antibiotic
agents which exhibit high bioavailibility are an acceptable
alternative to parenteral therapy.32 Several randomised
clinical trials have found similar cure rates in patients
treated with oral and parenteral antibiotic therapy.34,35 In
addition parenteral antibiotics are associated with an
increased incidence of moderate or severe side-effects.30
Preferred oral agents, based on clinical and pharmacoki-
netic data, include fluoroquinolones and trimethoprim-
sulfamethoxazole (cotrimoxazole).32 Studies involving
fluoroquinolones have found high cure rates, although
failure of treatment may occur in Pseudomonas or S.aureus
infections, especially when used as monotherapy.36 In
addition, it is a matter of concern that fluoroquinolones
have been associated with impaired bone healing and
these agents may need to be avoided in cases of septic non-
union or in the setting of post-infective reconstruction.37
Cotrimoxazole exhibits concentration-dependent killing,
therefore higher than usual doses (7–8 mg/kg/day
trimethoprim) are recommended in the treatment of
chronic osteomyelitis.38 De Barros et al. reported an
impressive 98% cure rate with 6 months of cotrimoxazole
therapy following surgical debridement, although it may
be argued that the extended duration of therapy may have
resulted in disease quiescence through suppression.39
Rifampicin achieves bone levels equivalent to serum
concentrations and when used in conjunction with other
agents there appears to be a clear benefit in terms of cure
rates.40,41 It should however never be used as monotherapy
due to the risk of the development of resistance. Sanchez
et al. reported a 100% cure rate in staphylococcal infections
with surgical debridement in conjunction with double the
standard dose of cotrimoxazole combined with rifampicin
for a mean of five weeks.42 Similarly, cotrimoxazole
combined with rifampicin achieved similar cure rates to
both linezolid with rifampicin, as well as eight weeks of
intravenous cloxacillin monotherapy, in the treatment of
chronic osteomyelitis and infections associated with
surgical implants.43,44 It is important to note that oral
dosing of β-lactam antibiotics results in serum levels of
less than 10% of parenteral administration. This pharma-
cokinetic characteristic raises concern regarding the ability
of β-lactams to reach adequate MIC in bone, despite the
fact that their penetration is better in infected than in
uninfected bone.45 Clindamycin exhibits good bone
penetration and many methicillin-resistant S. aureus
strains are susceptible to the agent. Despite these charac-
teristics there are no recent studies investigating the use of
clindamycin in the management of osteomyelitis. 
Figure 3. Fracture of a vascularised fibula graft which was used to manage a 20 cm bone defect. Union of the fracture was
achieved following gradual correction of the mechanical axis with the use of a hexapod external fixator.
In terms of the route of administration, 
oral antibiotic agents which exhibit high bioavailibility 
are an acceptable alternative to parenteral therapy
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Linezolid, the first antimicrobial in the new oxazo-
lidinone class, was initially received with much enthu-
siasm as a result of its high bioavailability following oral
administration and excellent activity against staphylo-
cocci, streptococci and vancomycin-resistant enterococci.
Unfortunately clinical studies have shown cure rates of
only 60% and prolonged used has been associated with
pancytopaenia, peripheral neuropathy and optic
neuritis.46,47 The use of linezolid is therefore typically
limited to patients with osteomyelitis resulting from
vancomycin-resistant enterococci or patients who are
intolerant of vancomycin.46 Daptomycin, a new
lipopeptide antimicrobial agent, exhibits good activity
against Gram-positive bacteria including methicillin-
resistant S. aureus and glycopeptide-resistant enterococci.
It has been studied extensively in the management of
osteomyelitis and has been shown to be a good salvage
option in cases which failed to respond to standard
therapy.48
The optimal duration of antimicrobial therapy following
surgical debridement remains unknown. The traditional
duration of treatment is four to six weeks. This is based on
experience with the management of acute osteomyelitis in
children, where extended periods of antibiotics are
required, as well as the results of animal studies which
illustrated that six weeks of antibiotics was effective in
sterilising diseased bone.49 This traditional recommen-
dation is also derived from the assumption that revascu-
larisation of bone following debridement takes about four
weeks.50 Several studies have failed to demonstrate
increased efficacy of extended duration antibiotic
therapy.51 Furthermore, the absence of standardised
treatment algorithms makes interpretation of the data
very difficult. Many studies did not include surgical
debridement or removal of surgical implants, and thus
this form of treatment should rather be viewed as
palliative intervention. Because of the historical absence of
standardised definitions and treatment strategies, older
antibiotic treatment protocols are inconsistent with our
current way of thinking. The duration of antibiotic
treatment should rather be based on the treatment strategy
selected, the realistic aim of treatment and the extent of the
surgical margin. In theory, curative management
strategies involving wide resection would only require a
short period of antibiotics in order to sterilise the
remaining soft tissue. In practice truly wide margins are,
however, very difficult to achieve. Traditional thinking
dictates a minimum of six weeks treatment in curative
treatment protocols involving marginal debridement.
Unfortunately there is insufficient evidence to make defin-
itive recommendations and further studies are required in
this respect.32 In palliative treatment strategies or in cases
treated with intra-lesional debridement extended periods
of antibiotics appear to remain appropriate. 
The second role of antibiotics in the management of
chronic osteomyelitis is disease suppression as part of a
palliative treatment strategy. This form of treatment
appears to be justified by the successful use of suppressive
antibiotics in peri-prosthetic infections of hip or knee
replacements.52,53 Success rates of between 60 and 75%
have also been reported in cases of infection associated
with osteosynthesis through the use of long-term anti-
biotics without surgical removal of the implants.38,54
The efficacy of suppressive treatment in chronic
osteomyelitis without an implant has, however, not been
determined. In addition many of the older studies looking
at long-term antibiotic therapy included patients with and
without surgical implants as well as surgically and non-
surgically managed patients. This lack of uniformity made
comparison of results impossible and, again, illustrates the
urgent need for the establishment of standardised nomen-
clature and treatment strategies in the management of
chronic osteomyelitis. 
Chronic suppressive antibiotic therapy forms the corner-
stone of palliative management in C-hosts. This form of
treatment typically involves antibiotics that are prescribed
for a period six months. If quiescence or sufficient
suppression is achieved the antibiotics can be stopped. If
the infection recurs after discontinuation of the therapy, a
lifelong suppressive regimen should be considered.50
Various antibiotic regimens have been investigated. Due
to the inferior results reported with single agents, and the
efficacy shown with the addition of a second agent in the
setting of implant-related infections, most chronic
suppressive regimens generally involve the combination
of two agents.55,56 Antibiotics used in suppressive regimens
include cotrimoxazole, rifampicin, ciprofloxacin,
cloxacillin, fusidic acid and clindamycin.38,45,57,58 Although
directed therapy according to culture and sensitivity
results is the ideal, this is frequently not practical and
possibly not necessary in order to achieve clinical quies-
cence. The available literature suggests that cotrimoxazole
and rifampicin can be considered as first line chronic
suppressive antibiotic therapy.33 If these agents fail to
achieve clinical suppression during the first six months,
second line therapy may be instituted in the form of
clindamycin or cloxacillin in combination with rifampicin,
ciprofloxacin or fusidic acid.
Conclusion
Over the past few decades considerable progress has been
made in terms of our ability to reconstruct post-infective
soft tissue and bone defects. Muscle or musculocutaneous
flaps appear to be superior to random-pattern flaps (i.e.
local flaps) in achieving resolution of infection and it is
now generally accepted that primary closure of the wound
may be performed at the same sitting as the debridement.
Several factors need to be considered when dealing with
post-infective bone defects, and the size of the defect
serves as a useful guideline when selecting the appro-
priate treatment strategy. The soft tissue scarring
associated with chronic osteomyelitis rarely permits acute
shortening beyond 2 cm. Good results have been reported
with cancellous grafting into an induced membrane and
the Masquelet technique may be utilised in cases with
bone loss of more than 2 cm. For bone defects larger than
4 cm distraction osteogenesis may be appropriate, while
free vascularised fibula grafts may have to be considered
for defects in excess of 12 cm.
In terms of antibiotic therapy clear evidence-based
guidelines are lacking, especially in terms of the selection
of the appropriate antibiotic agents, the optimal duration
of treatment and the ideal route of administration. Oral
antibiotic agents that exhibit high bioavailability appear to
be an acceptable alternative to parenteral therapy.
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Preferred oral agents, based on clinical and pharmacoki-
netic data, include fluoroquinolones, rifampicin and
trimethoprim-sulfamethoxazole. In theory, curative
management strategies involving wide resection would
only require a short period of antibiotics in order to
sterilise the remaining soft tissue. Traditional thinking
dictates a minimum of six weeks of treatment in curative
treatment protocols involving marginal debridement. In
palliative treatment strategies and in cases treated with
intra-lesional debridement, extended periods of antibiotics
remain appropriate.
The content of this article is the sole work of the authors. The
primary author has received a research grant from the South
African Orthopaedic Association for research relating to chronic
osteomyelitis.
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PART 3 
The importance of patient selection in curative management 
strategies 
Part 3 of this thesis investigates the outcome of a curative treatment strategy involving bone 
transport through an induced membrane with the aid of circular external fixation. Although 
the number of cases presented in this series was small, there were certain noteworthy findings. 
Despite the fact that antibiotic-impregnated PMMA spacers offer several theoretical 
biological advantages, their use did not translate into a clinically relevant improvement in the 
external fixation index. In actual fact, the procedure resulted in a considerable increase in 
external fixation time when compared with the more traditional Ilizarov methods.1 The 
theoretical mechanical advantages of the spacer however, appeared to be clinically relevant. 
Not only did the spacer act as a useful dead space management tool, it also facilitated the 
bone transport process by preventing soft tissue entrapment. It was not possible in this series 
to determine if local antibiotic elution was beneficial as a control group was not included. 
Despite the limitations of the study, the technique appears to be effective and we were able to 
achieve remission of infection in all cases. 
Our success in achieving resolution of infection was however, most likely not a result of 
therapeutic prowess. It is more likely that our success was the result of prudent patient 
selection. The patients included in this series of cases were selected according to the same 
host stratification system proposed in Part 4 of this thesis. This study therefore indicates that 
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patient selection is key in ensuring a successful outcome of curative treatment. In addition, 
this study also shows that once segmental resection and bone transport is embarked on it has 
to be carried through to completion, as the only alternative may be amputation. One patient 
was poorly motivated, non-compliant with rehabilitation and eventually requested 
amputation. This suggests that patient compliance and motivation should be included as a risk 
factor, that needs to be assessed during host stratification.  
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Development of an integrated approach 
In parts 1 and 2 of this thesis the limitations of existing classification systems and the lack of 
evidence-based treatment guidelines were highlighted. Part 3 illustrated the importance of 
patient selection in curative surgical treatment. Part 4 introduces a novel approach to adult 
chronic osteomyelitis which integrates a modified host stratification system with treatment 
strategy selection. 
The first step in developing this approach, involved refinement of the Cierny and Mader 
classification system.1 The aim was to remove ambiguity and apply pragmatic criteria during 
the classification process [Table 4.1]. In order to achieve this, modification of the criteria 
defining both the physiological class and anatomic type was required.  
The physiological classification of the host, as proposed by Cierny and Mader, was modified 
in order to standardize and improve objectivity of the stratification process. Although Cierny 
and Mader recognized the need for standardization in their original publication, no method 
was proposed.1 In the following study C-hosts were defined according to presence or absence 
of certain predetermined major and minor risk factors [Table 4.2]. The selection of these 
criteria was based on existing evidence and classification systems, as well as prior experience. 
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Table 4.1: Modified classification system for adult long bone chronic osteomyelitis. 
In terms of CD4 count in HIV infected patients, 350 cells/mm3 was selected as the cut-off 
between B and C-host classification. This value, which coincides with the WHO 
immunological definition of advanced HIV infection, was selected on the basis of practical 
considerations.2 Current treatment guidelines in South Africa dictate that retroviral therapy is 
instituted once the patient’s CD4 count falls below 350 cells/mm3.3 Although evidence 
remains scanty, it appears reasonable to institute antiretroviral treatment in patients with 
advanced HIV infection in an attempt to reduce the complication rate in non-emergent 
surgery.4,5 In addition, Aird et al. found an increased infection rate in open fractures in HIV 
positive individuals with a CD4 count below 350 cells/mm3.6 The incidence of postoperative 
infection has also been shown to be increased in patients with a CD4 count below 350 cells/
mm3.7,8 Likewise, an albumin level of less than 30g/L has been associated with an increase in 
postoperative complications and infections.9-11 Hyperglycemia has been associated with 
increased post-operative infection in both trauma and elective orthopaedic surgery and a 
HbA1c of 8% translates to an average blood glucose level of 10 mmol/L over the preceding 
Classification Characteristic
Physiology:
    Type A host No risk factors
    Type B host Less than three minor risk factors
    Type C host One major and/or three or more minor risk factors
Pathoanatomy:
    I   - Medullary No cortical sequestration 
    II  - Cortical Direct contiguous involvement of cortex only
    III - Combined (stable) Both cortex and medullary regions involved
    IV - Combined (unstable) As for III plus unstable prior to debridement
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three months.12,13 Cellulitis and abscess formation compromises the soft tissue envelope and 
temporarily precludes the performance of definitive surgery. [Table 4.2]  
Table 4.2: Risk factors assessed during host status determination 
With this classification system we aimed to address the element of uncertainty which may 
occasionally arise during the anatomical classification of the disease. In the original Cierny 
and Mader classification system, the differentiation between localized (type III) and diffuse 
(type IV) disease was based on the surgeon’s estimation of stability following debridement.1 
This estimation can however be problematic, especially for training orthopaedic surgeons, as 
there are many factors that determine the extent of the debridement. Cierny and Mader did not 
provide specific guidelines regarding which cases required segmental resection.1 In theory 
compromised hosts are best treated with wide resection.14 Wide resection may however result 
Major Risk factors Minor systemic risk factors Minor local risk factors
CD4 count < 350 cells/mm3 HIV infection Poor soft tissues requiring flap
Albumin < 30 g/L Anaemia Chronic venous insufficiency
HbA1C ≥8% Smoking Peripheral vascular disease
Cellulitis or abscess formation Diabetes mellitus Previous radiation therapy
Malignancy at site of infection Rheumatoid arthritis Instability expected after surgery
Pathological fracture Chronic lung disease Adjacent joint stiff / arthritic
Chronic cardiac failure Heterotopic ossification
Common variable Immune 
deficiency
Segmental resection of >6cm 
required to achieve cure
Paraplegia / Quadriplegia






in segmental bone loss, requiring complex reconstruction procedures like bone transport or 
extensive bone grafts. These techniques are fraught with danger, especially in the 
compromised host and failure may result in unplanned amputation. The fact that the anatomic 
type of the infection and the extent of debridement was (according to the original Cierny and 
Mader classification system) not defined prior to surgery, created uncertainty during the pre-
operative counselling of patients. The modification of the anatomic staging which was used in 
this series relied on classification of the anatomic nature of the disease prior to debridement. 
The approach followed in our study involved maintenance of stability when present and 
therefore it was known in advance if reconstruction of a segmental bone defect would be 
required. A notable implication of this approach is that all septic non-unions were classified 
and treated as type IV chronic osteomyelitis.  
The final step of the proposed approach involved integrating the modified classification 
system with selection of the appropriate treatment strategy. This required the development of 
a treatment algorithm which incorporated the physiological status of the host, the presence of 
skeletal instability, the severity of impairment, as well as the concept of minimal necrosis 
osteomyelitis. 
In order to assess the efficacy of the proposed approach, the outcome of treatment (in terms of 
the resolution of infection) was retrospectively assessed. While previous studies focused on 
the outcome of curative treatment, we also report the outcome of palliative treatment 
strategies.1,15-17 To the best of our knowledge this study is the first to report the outcomes in 
all treatment groups. This allowed evaluation of the approach as a whole, which provided 
insight into the relevance of the proposed treatment strategy selection process. 
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Assessment of integrated approach 
The major limitation of the preceding study was the retrospective study design. In order to 
address this limitation, a prospective study was undertaken to assess the outcomes of 
treatment according to the proposed integrated approach. Data analysis from the retrospective 
series (Chapter 7) identified the need for further development of both the classification system 
and the treatment selection algorithm. In order to facilitate the treatment strategy selection 
process the classification system was modified to include impairment severity and the 
presence of an infection nidus [Table 5.1]. 
Table 5.1: Classification system used in the prospective series.
Classification Characteristic
Physiological:
    Type A host No risk factors
    Type B host Less than three minor risk factors
    Type C host One major and/or three or more minor risk factors
Pathoanatomy:
    I   - Medullary No cortical sequestration 
    II  - Cortical Direct contiguous involvement of cortex only
    III - Combined (stable) Both cortex and medullary regions involved
    IV - Combined (unstable) Same as III plus unstable prior to debridement
Nidus:
    Sequestrum Cortical sequestrum present
    Implant Biofilm-based infection in the presence of an implant
    No identifiable nidus Minimal necrosis osteomyelitis
Impairment:
    Minimal Patient able to perform ADL
    Severe Unable to perform ADL
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For the treatment selection algorithm to remain relevant in both haematogenous and post-
operative infection, the concept of minimal necrosis osteomyelitis required further expansion. 
Minimal necrosis osteomyelitis was defined as chronic infection in the absence of an 
identifiable nidus of infection, albeit a sequestrum or orthopaedic implant. This definition 
therefore also catered for the scenario of an infected tibial nail in the presence of a united 
tibial fracture, where removal of the nail is required as part of a curative treatment strategy. 
The second item added to the proposed classification system was the extent of impairment as 
a result of the disease. This step was required in order to clarify the decision making process 
during treatment strategy selection [Figure 5.1]. 
Figure 5.1: Treatment selection algorithm. 
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In addition to the changes that were made in the classification system, certain additional risk 
factors were added to the list of host-defining criteria [Table 5.2]. These were identified in the 
retrospective series (Chapter 7) amongst patients in whom the initial treatment plan failed. 
Table 5.2: Major and minor host-defining criteria used in prospective series. 
* Risk factors identified in retrospective series 
The final treatment algorithm, implemented in the prospective series, incorporated the 
physiological status of the host, the presence of skeletal instability, the severity of impairment, 
Major risk factors Minor systemic risk factors Minor local risk factors
CD4 count < 350 cells/mm3 HIV infection Poor soft tissues requiring flap
Albumin < 30 g/L Anaemia Chronic venous insufficiency
HbA1C ≥ 8% Smoking Peripheral vascular disease
Cellulitis or abscess formation Diabetes mellitus Previous radiation therapy
Malignancy at site of infection Rheumatoid arthritis Instability expected after surgery
Pathological fracture Chronic lung disease Adjacent joint stiff / arthritic
Chronic cardiac failure Heterotopic ossification
Common variable Immune 
deficiency
Segmental resection of >6cm 
required to achieve cure
Paraplegia / Quadriplegia Failed reconstruction elsewhere *
Drug or substance abuse Foot involvement *
Chronic corticosteroid use Pelvic involvement *
Active tuberculosis Adjacent joint involved *
Ischemic heart disease
Cerebrovascular disease
Compliance and motivation *
Age > 65 *
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as well as the concept of minimal necrosis osteomyelitis. Furthermore, additional emphasis 
was placed on risk factor modification [Figure 5.1]. 
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Chapter 8: The outcome of treatment of chronic osteomyelitis following an 
integrated approach 
Marais LC, Ferreira N, Aldous C, Le Roux TLB.  
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The outcome of treatment of chronic osteomyelitis following an integrated 
approach 
Abstract 
Chronic osteomyelitis of long bones can be particularly challenging to treat in adult patients. 
While several classification systems have been proposed, none has been universally accepted. 
Popular classifications have failed to provide objective and pragmatic guidelines for selection 
of the appropriate treatment strategy. In this study we investigate the short-term treatment 
outcome in adult patients with long bone chronic osteomyelitis, where a modified host 
classification system was integrated with treatment strategy selection through a novel 
management algorithm. Prospective evaluation was performed of adult cases with chronic 
long bone osteomyelitis treated at a tertiary level tumour, sepsis and reconstruction unit. 
Following clinical, radiological and biochemical evaluation, patients were classified using a 
modified version of the original Cierny and Mader classification system. The physiological 
host status was modified to provide a more pragmatic and objective C-host definition. This 
classification system was integrated with treatment strategy selection using a novel 
management algorithm. Twenty-six of the 28 enrolled patients were available for follow-up. 
The median patient age of was 36.5 years (range 15-72 years). Three patients (12%) were 
classified as A-hosts, eleven patients (42%) as B-hosts and twelve (46%) as C-hosts. Seven 
patients (27%) were HIV positive with a mean CD4 count of 401cells/mm3 (range 220-986 
cells/mm3). Nine patients (35%) were smokers and three patients (12%) had 
hypoalbuminemia. Fourteen patients (54%) were managed palliatively and 11 patients (42%) 
were managed through the implementation of a curative treatment strategy. One patient 
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required alternative treatment in the form of an amputation. The overall success rate was 
92.3% (95%CI: 74.9-99.1%) at a minimum of 6 months follow-up. Remission was achieved 
in all [11/11] patients treated curatively (one sided 95% CI: 73.5-100.0%). Palliative treatment 
was successful in 86% [12/14] of cases (95% CI: 57.2-98.2%). In patients with lower limb 
involvement there was a statistically significant improvement of 28.3 (95% CI:21.0-35.7; SD 
17.0) in the AAOS Lower Limb Outcomes Instrument score (p-value<0.001). The integrated 
approach proposed in this study appears to hold some promise in serving as a useful guideline 
to the management of chronic osteomyelitis of long bones in adult patients in the developing 
world. Further investigation is required to validate the approach and additional development 
of the algorithm may be required in order to render it useful in other clinical environments. 
Keywords 
Osteomyelitis, Chronic, Classification, Outcome, Management. 
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Introduction 
Long bone chronic osteomyelitis can be particularly challenging to treat in adult patients. The 
typical causative organisms possess characteristics which render them more resistant to the 
host’s immune response and antibiotic therapy. Bacteria may persist in a biofilm-based colony 
or intracellular, concealed within osteoblasts.1,2 While chronic haematogenous osteomyelitis 
is typically not associated with skeletal instability, it frequently involves a large segment of 
bone. Post-traumatic contiguous osteomyelitis is often complicated by the presence of 
instability or a compromised soft tissue envelope. Lastly, there are frequently systemic risk 
factors present in the host which compromise their immune system’s ability to effectively 
combat the infection. 
Several classification systems have been proposed, but none has been universally accepted.3,4 
Although the Cierny and Mader classification has been the most popular, the stratification of 
the physiological status of the host remains problematic.5,6 The definition of a C-host, 
according to this classification, is subjective in nature and is dependent on the treating 
surgeon’s ability to predict the patient’s response to a therapeutic intervention.7 The 
differentiation between a B and C-host is important as it identifies patients who should be 
treated curatively or palliatively.3 In addition, the lack of standardization in host classification 
has made comparison of results from different studies challenging.8 
No evidence-based guidelines exist on the treatment of chronic osteomyelitis in adults.3 There 
is no single treatment regimen or surgical procedure which is appropriate for all patients.9 
Essentially the choice is between a curative, a palliative or an alternative approach. Curative 
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treatment usually involves surgical debridement with or without complex reconstructive 
procedures and short-term pathogen-directed antimicrobial therapy.10 Palliative treatment on 
the other hand typically involves long-term chronic suppressive antibiotic therapy (CSAT) 
and, rarely, intra-lesional or minimally invasive surgical intervention.11 An alternative 
treatment strategy is occasionally indicated and may comprise either amputation of the limb 
or a combination of surgical intervention and chronic suppressive antibiotic therapy. The main 
difficulty lies in choosing the correct treatment strategy in each patient. This process is further 
complicated by the aforementioned lack of standardization in host stratification. 
The limitations of existing classification systems, as well as the lack of evidence based 
guidelines, prompted us to develop a classification system and treatment algorithm which 
would assist in treatment strategy selection in a developing country. In this study we 
investigate the short-term outcome of treatment in adult patients with long bone chronic 
osteomyelitis, where a modified host classification system was integrated with treatment 
strategy selection through a novel management algorithm. 
Materials and Methods 
A prospective study was performed on 28 consecutive patients with long bone chronic 
osteomyelitis treated by the Tumour, Sepsis and Reconstruction Unit at Grey’s Hospital in 
Pietermaritzburg, South Africa. All adult patients older than 13 years of age and with a 
minimum follow-up of six months were included in the series. Patients with infections 
involving the foot or hand, atypical organisms (including tuberculosis and fungal infections) 
!101
and arthroplasty-related periprosthetic infection were excluded from the study. Data were 
collected with regard to patient demographics, the cause and site of infection, the initial and 
final impairment, causative organisms, management strategy employed, follow-up period and 
outcome of treatment in terms of remission or suppression of infection. Impairment was 
assessed by means of the quickDASH scoring system for upper limbs or AAOS Lower Limb 
Outcomes Instrument (version 2.0) in the case of lower limb involvement.12,13 
For the purposes of this study chronic osteomyelitis was defined as an infection involving 
bone, with a duration of at least ten days, where the causative organisms were thought to have 
persisted either intracellularly or in interactive biofilm-based colonies. Periprosthetic 
infections were excluded from the study based on the current trend of classifying and treating 
arthroplasty related infections as a separate entity.14 Following clinical, radiological and 
biochemical evaluation, patients were classified according to a modified version of the 
original Cierny and Mader classification system [Table 1].7 In terms of the physiological 
status of the host, the Cierny and Mader classification system was modified in order to 
provide a more pragmatic and objective definition of a C-host. A patient was classified as a C-
host if one major or more than two minor risk factors were present [Table 2]. In order to 
remove any ambiguity during classification of the anatomical nature of the disease this was 
performed prior to, rather than following, the debridement. The impairment resulting from the 
disease and the nidus of infection was added to the classification as these factors were to be 
considered during the treatment selection process.  
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Table 1: Modified version of the original Cierny and Mader classification system that served 
to guide treatment strategy selection. 
Classification Characteristic
Physiological:
    Type A host No risk factors
    Type B host Less than three minor risk factors
    Type C host One major and/or three or more minor risk factors
Pathoanatomy:
    I - Medullary No cortical sequestration 
    II - Cortical Direct contiguous involvement of cortex only
    III - Combined (stable) Both cortex and medullary regions involved
    IV - Combined (unstable) As for III plus unstable prior to debridement
Nidus:
    Sequestrum Cortical sequestrum present
    Implant Biofilm-based infection in the presence of an implant
    No identifiable nidus Minimal necrosis osteomyelitis
Impairment:
    Minimal Patient able to perform ADL (activities of daily living)
    Severe Unable to perform ADL
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Table 2: Risk factors used to stratify the physiological status of the host. 
The modified classification system was integrated with treatment strategy selection through 
the implementation of a novel management algorithm [Figure 1]. C-hosts, as well as A or B-
hosts with minimal impairment, no identifiable source and no skeletal instability, were 
managed palliatively. All remaining A and B-hosts were treated curatively. C-hosts with 
severe impairment combined with skeletal instability were managed through the 
implementation of an alternative treatment strategy. This involved either amputation or 
chronic suppressive antibiotic therapy in combination with external fixation with or without 
intralesional debridement. 
Major risk factors Minor systemic risk factors Minor local risk factors
CD4 count < 350 cells/mm3 HIV infection Poor soft tissues requiring flap
Albumin < 30 g/L Anaemia Chronic venous insufficiency
HbA1C ≥ 8% Smoking Peripheral vascular disease
Cellulitis or abscess formation Diabetes mellitus Previous radiation therapy
Malignancy at site of infection Rheumatoid arthritis Instability expected after surgery
Pathological fracture Chronic lung disease Adjacent joint stiff / arthritic
Chronic cardiac failure Heterotopic ossification
Common variable Immune 
deficiency
Segmental resection of >6cm 
required to achieve cure
Paraplegia / Quadriplegia Failed reconstruction elsewhere
Drug or substance abuse Foot involvement
Chronic corticosteroid use Pelvic involvement






Figure 1: Treatment selection algorithm 
Curative treatment involved marginal or wide resection, dead space management, provision of 
bony stability, soft tissue reconstruction and/or skeletal reconstruction, in conjunction with 
pathogen directed adjuvant antibiotics for a period if six weeks. In cases without skeletal 
instability (Cierny and Mader anatomic type I, II and III lesions) the aim was to maintain 
stability through the performance of marginal debridement involving direct unroofing 
(tangential excision with high speed burr) and/or indirect unroofing (medullary reaming). In 
cases involving skeletal instability, wide (segmental) resection was performed and stability 
provided by circular external fixation. Dead space management techniques were tailored to 
the anatomic nature of the pathology. Continuous irrigation, as proposed by Lautenbach, was 
used in type I (medullary) post-operative infections.15,16 In type III lesions (stable combined 















































beads (Septopal® Merck, Darmstadt Germany) were used and removed at six to eight weeks. 
Post-operatively, all patients were treated with generic parenteral antibiotics in the form of 
Cefazolin and Imipenem until the seven day microscopy, culture and sensitivity (MCS) results 
became available. Oral antibiotic therapy, in the form of two agents which were tailored to the 
culture and sensitivity, was subsequently commenced and continued for a period of six weeks. 
Following this period, reconstruction of segmental bone defects in Cierny and Mader type IV 
lesions were undertaken if clinical and biochemical evaluation confirmed the absence of 
active infection. The treatment protocol dictated that the size of the bone defect would 
determine the nature of the subsequent skeletal reconstruction procedure. Defects less than 
1-2cm in magnitude were managed by acute shortening [Fig. 2]. In long bones other than the 
tibia, defects between 2 and 4 cm in size were managed using the Masquelet technique, 
involving autogenous bone grafting into an induced membrane. Tibial defects larger than 2 
cm and other gaps in excess of 4 cm were treated through the use of bone transport. 
Palliative treatment involved the use of chronic suppressive antibiotic therapy (CSAT) in the 
form of trimethoprim-sulfamethoxazole (800mg/160mg twice daily) and rifampicin (600mg 
daily). In cases where the general condition of the patient and local soft tissues allowed, an 
intralesional excision of discreet exposed sequestra was performed. In this series, all cases 
treated by an alternative treatment strategy required amputation of the limb. 
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(a)   !           !              (b)    !  
(c)   !      !  
Figure 2: X-ray images of a case involving pre-operative instability (anatomic type IV 
infection). (a) This 72 year old diabetic patient presented with a septic non-union of the 
humerus following multiple previous surgeries. (b) Post-debridement reconstruction involved 
acute shortening, bone graft and circular external fixation. (c) Radiological images following 
external fixator removal. 
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Following a minimum six month follow-up period treatment success or failure was 
determined. Success was defined as achievement of remission through a curative treatment 
strategy or attainment of suppression in patients treated palliatively. Remission was defined as 
the absence of clinical signs of infection.8 Suppression was defined as subjective resolution of 
infection symptoms and signs, from the patient point of view, to the extent that the patient 
required no additional treatment. Treatment failure was defined as the failure to achieve the 
predetermined goal (remission or suppression). The outcome was also reported as failure if 
unplanned re-operation was required or if the patient was dissatisfied with the outcome. 
Data were analyzed using Stata 13.0 (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP). Continuous variables were summarized using mean and 
standard deviation values. If the variable was skewed or outlying values were present, then 
the median and interquartile range was used instead. Category variables were summarized 
using frequency tables. 95% confidence intervals were constructed around sample point 
estimates. Change in AAOS Lower Limb Outcomes Instrument score from initial assessment 
to final assessment was compared using a paired t-test. A p-value of <0.05 was considered 
statistically significant for all tests. 
Ethical approval was obtained from the relevant ethics review boards prior to commencement 
of the study. 
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Results 
Twenty-six of the 28 enrolled patients were available for follow-up at six months. The median 
patient age was 36.5 years (range 15-72 years; interquartile range 24 years). Seven patients 
had chronic haematogenous osteomyelitis, eight had post-operative infections, nine developed 
chronic osteomyelitis after open fractures and two patients developed contiguous chronic 
osteomyelitis as a result of direct local extension. The tibia diaphysis was the most commonly 
involved site [Table 3].  
Table 3: Infection site. 
Culture results, from tissue samples taken at the time of debridement in patients who were 
treated curatively, revealed a variety of causative organisms [Table 4] 
Infection site Number of patients
Tibia diaphysis 12 (46%)
Femur diaphysis 8 (30%)
Tibial plateau 2 (8%)
Humerus diaphysis 2 (8%)
Tibial plafond 1 (4%)
Ulna shaft 1 (4%)
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Table 4: Microorganism cultured from tissue samples taken during debridement in patients 
treated curatively. 
Classification 
Three patients (12%) were classified as A-hosts, eleven patients (42%) as B-hosts and twelve 
(46%) as C-hosts. Six patients were classified as C-hosts due to the presence of one major risk 
factor and six patients on the basis of the presence of three or more minor risk factors. Of the 
twelve C-hosts, six had both a major and more than 2 minor risk factors present. Seven 
patients (27%) were HIV positive with a mean CD4 count of 401cells/mm3 (range 220-986 
cells/mm3; standard deviation (SD) 238 cells/mm3). A variety of additional risk factors were 
identified amongst the patients enrolled [Fig. 3].  











Multiple organisms 1 
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Figure 3: Risk factors identified. 
 
Nine patients (35%) were smokers and three patients (12%) had hypoalbuminemia. The soft 
tissues were considered to represent a significant risk factor for the development of 
complications following surgery, if not addressed by flap or other means, in ten patients. 
Cellulitis and abscess formation, precluding the performance of definitive surgery was present 
in three patients. Peripheral vascular disease or chronic venous insufficiency with 
lipodermatosclerosis was present in three patients. The infection involved the adjacent joint in 
five cases and there was significant loss in range of motion of the adjacent joint in an 
additional two patients. Other risk factors included previous radiation, chronic renal failure 
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requiring dialysis and chronic corticosteroid use in one patient, diabetes mellitus in one 
patient and age over 65 years in two patients. In terms of the anatomic nature of the disease, 
twenty patients had type III infection, five patients had pre-operative instability and in one 
patient the infection was confined to the medullary cavity. The mean initial AAOS Lower 
Limb Outcomes score in patients with lower limb involvement was 58.2 (range 21-100; SD 
22.9). In three cases the upper limb was involved, with a mean initial quickDASH score of 
18.2 (range 2.3-29.5) [Table 5]. 
Management  
Fourteen patients (54%) were managed palliatively and 11 patients (42%) were managed 
through the implementation of a curative treatment strategy. One patient required alternative 
treatment in the form of an amputation. This patient had infection and bone loss following a 
neglected open fracture and was classified as a C-host on the basis of the presence of two 
major and two minor risk factors. The palliative treatment group consisted of eleven C-hosts 
and three B-hosts who had stable lesions with minimal impairment and no identifiable 
sequestra. All patients in the palliative treatment group received chronic suppressive antibiotic 
therapy - trimethoprim-sulfamethoxazole (800mg/160mg twice daily) and rifampicin (600mg 
daily) - for a period of three to six months. One patient, who had an exposed sequestrum in 
the region of the tibial plateau, required an additional intralesional excision (simple 
sequestrectomy). 
In the curative treatment group, surgical intervention involved marginal debridement (direct 
and/or indirect unroofing) in ten patients. Wide (segmental) resection of the ulna diaphysis, 
without subsequent reconstruction, was performed in one patient. Dead space management 
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involved a modified Lautenbach continuous irrigation system in six cases, PMMA beads in 
four patients and local muscle flap in one case. Primary soft tissue closure was obtained in all 
curative cases. In the two patients, in whom skeletal stabilization and reconstruction was 
required, acute shortening and Ilizarov circular external fixation was performed. Union was 
achieved in both of these cases. All patients treated curatively received a combination of two 
oral antibiotics for a period of six weeks. 
Outcome 
The overall success rate was 92.3% (95%CI: 74.9-99.1%) after a minimum of six months 
follow-up. Remission was achieved in all [11/11] patients treated curatively (one sided 95% 
CI: 73.5-100.0%). Palliative treatment was successful in 86% [12/14] of cases (95% CI: 
57.2-98.2%), with suppression in 36% and remission in the remaining 64% of these patients. 
The overall mean final AAOS Lower Limb Outcomes score was 86.6 (range 51-100; SD 
14.5). This equated to a statistically significant (p-value<0.001) mean improvement of 28.3 
(95% CI:21.0-35.7, SD 17.0). In the upper limb the mean final overall quickDASH score was 
75 (range 72.5-86.4), with a mean improvement of 54.3 (range 45.5-84.1). There was 
comparable improvement of the functional outcome scores in the palliative and curative 
treatment groups [Table 5]. 
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Table 5: Functional outcome. 
(i) AAOS Lower Limb Outcomes Instrument, (ii) quickDASH, (iii) paired t-test  
Both treatment failures occurred in the palliative treatment group. One failure occurred in a 
patient who required regular dialysis as a result of Goodpasture syndrome. This patient had 
extensive involvement of the entire femoral diaphysis following prior irradiation, with 
peripheral vascular disease and avascular necrosis of the femoral head. A hip disarticulation 
was required following abandonment of the palliative treatment protocol. The second failure 
occurred in a patient who developed post-traumatic osteomyelitis following an open tibial 
Category n Mean Range SD 95% CI p-value iii
Overall lower extremity i 23
    Initial 58.2 21 - 100 22.9 48.2 - 68.1
    Final 86.6 51 - 100 14.5 80.3 - 92.9
    Improvement 28.3 0 - 49 17.0 21.0 - 35.7 <0.001
Overall upper extremity ii 3
    Initial 18.2 2.3 - 29.5
    Final 75 72.5 - 86.4
    Improvement 54.3 45.5 – 84.1
Palliative group i 14
    Initial 51.1 28 - 100
    Final 92.5 51 - 100
    Improvement 25.5 0-54
Curative group i 8
    Initial 61 34 - 94
    Final 91 74-100
    Improvement 27.5 6-48
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fracture with compartment syndrome. Palliative treatment was instituted in this patient as a 
result of the presence of multiple risk factors which included HIV infection (CD4 count 518 
cells/mm3), cigarette smoking, poor soft tissue condition and age >65 years. 
Discussion 
Chronic osteomyelitis management continues to pose a major challenge to orthopaedic 
surgeons.11 The Mayo Clinic previously reported a 20% failure rate in the management of 
chronic infections.17 Twenty years later the disease remains difficult to cure, as was recently 
illustrated in a Cochrane review on the topic of antibiotic therapy in chronic osteomyelitis.18 
The combined remission rate, in this analysis of four randomized controlled trails, was 78.8% 
at 12 months. Specialized units have, however, been able to achieve superior results. Cierny 
for example, achieved success in 84% of patients managed curatively at two year follow-up.10 
The Bone Infection Unit in the United Kingdom reported an impressive cure rate of 90% at 5 
years follow-up.9 While the multidisciplinary nature of the service offered by these 
specialized units is bound to improve outcomes, appropriate surgical candidate selection may 
also play a role.  
Without a pragmatic and objective definition of a C-host (who should be palliated) the 
selection of a curative (surgical) treatment strategy, according to the Cierny and Mader 
classification system, is essentially based on prior clinical experience.7 According to this 
approach the expected outcome of a curative strategy should offer a distinct advantage over 
symptomatic treatment or amputation, in order to justify the potential morbidity and risks 
involved in limb salvage surgery.7,10 Selecting candidates for surgery on this basis clearly 
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requires considerable experience, as it is based on a prediction of the patient’s response to 
treatment. The experience gained in specialized units will therefore improve the success rate 
of curative treatment strategies due to, amongst other factors, improved surgical candidate 
selection. The approach followed in our study, was developed to serve as a guideline for 
treatment of chronic osteomyelitis in a resource-poor clinical environment, where treatment 
by specialized units is not always easily accessible.  
In a previous retrospective series of 116 cases we were able to achieve an overall success rate 
of 91% at 18 months follow-up, through the application of an approach which involved 
integration of pragmatic host stratification with treatment strategy selection (unpublished 
data). With this study we aimed to perform a preliminary validation of a similar approach, in a 
prospective fashion. After a minimum of 6 months follow-up we were able to achieve an 
overall success rate of 92%, with 100% remission in the curative group and 86% suppression 
(or better) in the palliative group. These results are comparable to those achieved in our 
retrospective series, where curative and palliative treatment was successful in 92% and 89%, 
respectively. 
Although these results appear promising, caution is still advisable with regard to the 
widespread implementation of this approach. It should be kept in mind that the proposed 
classification system and treatment algorithm was designed for use in the developing world. It 
is therefore unlikely to be suitable in the developed world without further improvement or 
modification. Apart from the high incidence of HIV infection and hypoalbuminemia in our 
series, the pattern of causative organisms identified in our cases appears to differ somewhat 
from that seen in the developed world.19  
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Additional problems may also arise when the algorithm is tested in a wider range of patients. 
In one case in this series, the treatment algorithm was deemed to be inadequate as it 
prescribed chronic suppressive antibiotic therapy (CSAT) in a C-host (on the basis of the 
presence of skeletal stability), where amputation was going to be inevitable. This algorithm 
error was however on the conservative side and in many C-hosts without skeletal instability 
CSAT may suppress the disease to the extent that amputation may not be required. 
Furthermore, the proposed host stratification criteria could result in the initiation of palliative 
care in patients who may possibly have been able to cope with curative treatment. This 
approach may however, hold some benefit as it emphasises the importance of host factor 
modification prior to surgical intervention. Many high risk cases ,who may initially be 
classified as C-hosts, will become candidates for curative treatment (B-hosts) following 
implementation of the appropriate interventions aimed at risk factor reduction. 
There are further limitations to this study. The heterogeneous nature of the disease demands a 
much larger series of cases to determine if the algorithm is truly appropriate. The follow-up 
period in this series is too short to determine the ultimate success rate and our results are 
likely to deteriorate over time due to infection recurrence. While deterioration can be 
expected in both groups, it is bound to be more pronounced in the palliative group. Long term 
follow-up will be required to shed more light on this subject. The lack of a control group 
represents a further limitation. Randomizing high risk patients to high or low risk 
interventions, in order to identify which factors are associated failure (amputation), presents 
obvious ethical concerns. Future comparative studies will, however, be facilitated by the fact 
that we have provided a standardized host stratification system.  
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Despite these limitations, preliminary results suggest that our proposed approach may be 
useful in certain clinical environments. Our modified classification system may be more 
relevant to clinicians inexperienced in the management of chronic osteomyelitis, as it is less 
dependent on estimation of the response to treatment or the prediction of instability following 
debridement.7 Another important potential benefit of this approach is that standardized host 
stratification may enable the comparison of results from future studies. It may thus become 
possible to compare the outcome of different interventions or strategies,if the physiological 
host status was classified using the same pre-defined pragmatic criteria. This may in turn 
allow us to answer many of the questions that remain regarding the management of adult 
chronic osteomyelitis.8 
Conclusion 
The integrated approach proposed in this study appears to hold promise in the management of 
chronic long bone osteomyelitis in adult patients in the developing world. Further 
investigation is required to validate the approach and additional algorithm development may 
be required in order to render it useful in other clinical settings.  
The corresponding author has received a research grant from the South African Orthopaedic 
Association for research relating to chronic osteomyelitis. 
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Chapter 9: Conclusion  
9.1. Limitations of previous classification systems 
The absence of evidence-based guidelines for chronic osteomyelitis treatment in adult patients 
has been highlighted in the recent literature.1 Although both curative and palliative 
management options have been advocated, selection of the appropriate treatment strategy can 
be challenging. Embarking on a curative protocol, for example, in a compromised host who is 
unable to withstand the metabolic and immunological demands of complex limb 
reconstructive process may result in therapeutic failure. Failure of a curative treatment 
strategy, especially if it involves bone transport, can in some cases be impossible to salvage 
and result in unplanned amputation. This point was illustrated in Chapter 6, where the failure 
of a curative treatment strategy resulted in limb amputation. 
The clinical manifestations of chronic osteomyelitis result from the complex interplay of the 
host’s immune defense system and the biofilm-based bacterial colony on a sequestrum or 
surgical implant.2 The host’s physiological status not only determines the clinical course of 
the disease, but also serves as the primary indicator of the patient’s ability to effect healing of 
bone and soft tissues, as well as their ability to launch an effective immune response in 
conjunction with antibiotic therapy. Without a competent immune response from the host an 
attempt at eradication of the infection may be futile.3 
Cierny and Mader recognized the physiological status of the host as a crucial factor in the 
decision-making process, during the development of their UTMB classification system.4 The 
authors recommended palliative treatment in C-hosts, but failed to provide discreet or 
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pragmatic criteria by which to define a C-host. They acknowledge this fact by stating that 
there would be a wide variation in surgical candidate selection until there was standardization 
of this concept. The absence of such criteria has not only made treatment strategy selection 
problematic, it has also made teaching the subject to students and trainees challenging. Cierny 
and Mader’s definition of a C-host, as a patient in whom treatment or the results of treatment 
are expected to be worse than the disease itself, required an accurate estimation of a patient’s 
response to any particular intervention.4 Selection of the appropriate treatment strategy based 
on this definition clearly required considerable experience, which made treatment selection 
difficult for students or inexperienced clinicians.  
Romanò et al. also recognized the shortcomings of Cierny and Mader’s host classification 
during the compilation of their classification system.5 Their seven item comprehensive 
classification system (SICCS) is descriptive in nature and incorporates several existing 
classification systems. In contrast with the Cierny and Mader classification system it was not 
designed to guide management, but is rather intended for didactic and scientific purposes. In 
an attempt to circumvent the problems associated with the Cierny and Mader host 
classification, the authors preferred to use the McPherson host classification system and 
subdivided patients according to age (less than 2 years, less than 14 years and more than 14 
years of age). The McPherson system divides patients into three classes, A, B, or C, based on 
the number of co-morbid conditions that a patient has in common with a list of 14 immune-
compromising factors.6 Patients with no compromising factors were placed in class A, while 
patients in class B had less than 3 compromising factors. Class C patients were defined as 
having three or more compromising factors and/or one of the following conditions: an 
absolute neutrophil count less than 1000/mm3, a CD4 count less than 100 cells/mm3, 
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intravenous drug abuse, chronic active infection at another site or dysplasia/neoplasm of the 
immune system. In our retrospective series we noted a poor agreement between the 
McPherson classification and our modification of the Cierny and Mader system in terms of C-
host classification. This was most likely due to the fact that McPherson system was developed 
specifically for use in the planning of 2nd stage revision arthroplasty in patients with 
periprosthetic joint infection following total hip replacement. In addition, the list of criteria 
proposed by McPherson is conservative and may not be appropriate when applied to chronic 
osteomyelitis in general. Several criteria have been omitted, with specific reference to patient 
impairment, the state of the soft tissue envelope, arterial and venous sufficiency, age, diabetic 
control and nutritional status. All of these factors may however need to be considered during 
the decision making process in chronic osteomyelitis. 
In order to the address the limitations of the aforementioned classification systems the 
development of a novel approach to chronic osteomyelitis was required. However, in order to 
remain clinically relevant a new classification system would need to poses the potential to 
guide patient management. The ideal approach would therefore integrate patient classification 
with appropriate treatment strategy selection in a logical and reproducible manner. 
9.2. Developing an integrated approach to adult chronic osteomyelitis 
The lack of standardization in host classification, and therefore treatment strategy selection, 
has made the interpretation and comparison of previously published results problematic.1,2,7,8 
The provision of standardized, pragmatic definitions would, firstly, enable the validation (or 
invalidation) of the results of the studies contained in this thesis. Secondly, if these definitions 
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were adopted by future researchers in the field of adult chronic osteomyelitis, it would enable 
direct comparison of different treatment interventions. In order to increase objectivity and 
standardize host stratification, as well as treatment strategy selection, the definition of the 
disease itself, the characterization of the C-host and the definition of cure, required 
clarification. 
9.2.1. Defining chronic osteomyelitis 
Chronic osteomyelitis is not a homogenous entity but consists of various clinical conditions 
with multiple causes.9 Numerous definitions have been proposed, but controversy remains 
and the inconsistent definition of the disease has made it difficult to compare different 
investigation and treatment methods.1 A standardized definition was required to clarify which 
clinical scenarios should be termed chronic osteomyelitis and thus treated according to the 
proposed treatment algorithm.  
The definition proffered by Cierny, where the disease is characterized by the presence of 
biofilm, appears relevant as it is based on a universally applicable pathogenesis.2 This 
definition however, has certain practical limitations. By defining chronic osteomyelitis as a 
biofilm-based infection it becomes necessary to determine the timescale of biofilm formation 
in order to distinguish acute from chronic osteomyelitis. The answer may have important 
clinical implications: At what stage, for example, should an open fracture with devitalized 
bone be classified as chronically infected and thus chronic osteomyelitis treatment protocols 
implemented?  
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Biofilm formation is a complex process which is modulated by several factors including 
nutritional and environmental conditions.10 In addition, the process is possibly genetically 
programmed within the offending bacteria.11 Our knowledge of biofilms, though, is mostly 
based on the results of in vitro experimentation. In vivo biofilms exhibit several characteristics 
that differ significantly from what is predicted by our current in vitro models. Key differences 
include their smaller size and the fact that in vivo biofilm matrix does not necessarily need to 
be produced by the bacteria themselves.12 An obvious reason for these differences is the 
absence of immunological defence mechanisms in in vitro models. In vitro studies suggest 
that staphylococcal biofilm formation can occur within 24 to 48 hours of bacterial 
contamination.13 The question arises whether in vivo biofilm formation occurs at the same 
pace.  
Through the use of variable-pressure scanning electron microscopy, S. aureus biofilm 
formation has been illustrated within 7 days of infection in an animal model.14 The process is 
however continuous and the influence of the hosts immune response needs to be considered. 
Li and co-workers eloquently illustrated that, although in vivo biofilm formation is initiated 
within 48 hours after inoculation, the resulting acquired immune response starts limiting 
bacterial growth to a biofilm growth pattern from day 11.15  
It therefore appears that the temporal definition proposed in 1997 by Lew and Waldvogel, 
who defined chronic osteomyelitis as infection remaining for longer than ten days, also 
remains relevant.16 We therefore adopted a combination of the definitions suggested by 
Cierny and Waldvogel, in the studies contained within this thesis. Chronic osteomyelitis was 
thus defined as an infection involving bone, with a duration of at least ten days, where the 
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causative organisms is thought to have persisted either intracellularly or in interactive biofilm-
based colonies. This definition was thought to be specific enough to be reproducible, while 
still recognizing the importance of the underlying pathogenesis. 
Two additional clinical scenarios required special consideration. The first of these was “early 
post-operative infection following osteosynthesis”. Romano et al. have proposed a separate 
classification system and treatment approach to this entity.5,17 According to this classification 
system, conservative management was suggested for infection following osteosynthesis, if the 
construct was estimated to be stable. Stability is, however, not the only determinant of bony 
union. Although a fractured tibia with bone loss which was nailed with a fracture gap might 
be considered stable, it may still go on to septic non-union. In order to deal with this 
contingency, we propose that the potential for fracture union should rather be assessed. If the 
fracture fixation is deemed unstable or inadequate and union of the fracture is considered 
unlikely the diagnosis of chronic osteomyelitis should be deemed appropriate. When the 
fracture is however considered to be in the optimal bio-mechanical environment, and union is 
likely to occur, the standard chronic osteomyelitis algorithm should be deemed inappropriate 
and chronic suppressive antibiotic instituted until union. Once union is achieved in these 
patients, the chronic osteomyelitis protocol can implemented in order to manage on-going 
infection. 
The second clinical scenario which required special consideration was so-called “minimal 
necrosis osteomyelitis”. Although Cierny and Mader recognized this entity, they did not 
provide specific guidelines regarding its management.4 In this thesis we attempted to 
incorporate the treatment of this clinical scenario in our proposed algorithm. Thus our 
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definition of chronic osteomyelitis included the entity known as “minimal necrosis 
osteomyelitis”.  
9.2.2. Indications for surgery 
The indication for surgery, according to the approach proposed in this thesis, is based on the 
treatment aim. While surgery was always employed in cases receiving curative treatment, 
palliative treatment rarely involved surgery. Furthermore, when surgery was employed in the 
palliative treatment group it was always intralesional (minimally invasive) in nature.18 In 
order to develop a comprehensive treatment algorithm a third therapeutic option, namely 
alternative treatment, was required. This treatment arm dealt specifically with septic non-
unions in C-hosts and included amputation as a treatment option. Prior experience identified 
the need to also include an intermediate treatment option in the alternative treatment arm, 
involving chronic suppressive antibiotic therapy combined with circular external fixation with 
or without minimal debridement. Only a small number of patients in our retrospective series 
(10% of cases), were subjected to this treatment option (Chapter 7).  
The selection of the appropriate surgical intervention (curative, palliative or alternative) was 
primarily based on the physiological status of the host. Because only A and B-hosts were 
treated curatively there was an obvious need to accurately define the C-host. When taking into 
account that an A-host is a patient without any risk factors and that B-hosts are all the patients 
who are not an A or C-host, it stands to reason that by accurately defining the C-host, 
standardization of host stratification would be achieved across the entire spectrum of patients 
with chronic osteomyelitis. 
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9.2.3. Defining the C-host  
The provision of a pragmatic and objective C-host definition was central to the research idea, 
as the differentiation between A/B and C-hosts was integral to treatment strategy selection. 
The provision of such a definition necessitated the refinement of the Cierny and Mader host 
stratification system. According to the integrated approach, a C-host was defined as a patient 
with either one major and/or three or more minor risk factors (Chapter 8).  
The selection of these criteria was based on existing evidence, prior experience and the list of 
factors previously suggested by Cierny and Mader.4 While these criteria were developed with 
the South African clinical setting in mind, the principle of objective host stratification could 
also be beneficial in other clinical environments as it would enable the comparison of studies. 
In order to allow comparison of future results it would, however, also be necessary to 
standardize the definition of successful outcome. 
9.2.4. Defining a successful outcome 
In the studies contained within this thesis, success of a curative treatment strategy was defined 
in line with the definition proposed by Lazzarini et al. and the Infectious Disease Society of 
America (IDSA).19 Successful outcome of curative treatment was thus defined as the absence 
of signs of infection, from an objective (the treating physician’s) point of view.  
The outcome of palliative treatment strategies has not been studied previously, which would 
explain the absence of a successful outcome definition with palliative management. As is the 
case in oncology, a similar outcome cannot be expected from a curative and palliative 
strategy. The aim of palliative treatment is typically to provide symptomatic relief or 
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improvement. Therefore, it appeared reasonable to define palliative treatment success from a 
subjective (the patient’s) point of view. We therefore defined success as symptom 
improvement to the extent that the patient was satisfied with the outcome and requested no 
additional treatment. 
9.3.Treatment outcomes using an integrated therapeutic approach 
Chronic osteomyelitis in adults is notoriously difficult to treat. A recent Cochrane review, 
comparing the efficacy of oral and intravenous antibiotics following surgical debridement, 
found an overall remission rate of 78.8% at 12 months.7 Dedicated units and experts in the 
field of chronic osteomyelitis have, however, been able to achieve superior results. Cierny and 
Mader, through the application of their classification system, were able to achieve success in 
93.6% of patients who underwent limb-salvage procedures.1 Primary amputation was 
performed in 46 of the 189 (24%) patients who received definitive treatment in their series. 
Although the authors stated that 15% of their patients were classified as C-hosts, they did not 
report the outcome or prognosis in these patients. More recently, Cierny reported an overall 
success rate of 85% in curative treatment strategies at two year follow-up, with 96% success 
in A-hosts and 74% in B-hosts.2 Ten percent of cases in this series were managed by primary 
amputation. Again, C-host outcomes were not reported. The Bone Infection Unit in the United 
Kingdom reported that they were able to achieve a cure rate of 90% at 5 years follow-up, in a 
review article on chronic osteomyelitis.8 Treatment strategy selection and host stratification 
were, however, not discussed in this brief report of their outcomes. In addition the authors did 
not indicate what fraction of these cases was managed by amputation, which would have 
obviously improved cure rates.  
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Through the integration of a new classification and host stratification system with a treatment 
strategy selection algorithm we were able to achieve favourable outcomes in both high and 
low risk patients and, in addition, reduce the rate of amputation. At a minimum follow-up of 
12 months an overall success rate of 89.9% was achieved in our retrospective series (Chapter 
7). There was significant difference in outcome according to host status (p = 0.201) in this 
series, with no treatment failures in A-hosts, 6.7% failure in B-hosts and 15.7% failure in C-
hosts. In terms of the different treatment strategies, 93.5% success was achieved in the 
curative group, 87.2% in the palliative group and 87.5% in the alternative group (including 
amputations). Through the judicious implementation of palliative treatment strategies we 
were able to reduce the rate of primary amputation to 5%. In the South African clinical setting 
a low amputation rate is particularly relevant due to the limited availability of prosthesis. In 
addition, amputation is not accepted as a viable treatment option by many patients as a result 
of cultural or religious beliefs. 
A prospective study (Chapter 8), was subsequently undertaken in an attempt to validate the 
results of the retrospective series. The overall success rate was 92.3% at a minimum of 6 
months follow-up. Remission was achieved in all of the patients treated curatively. Palliative 
treatment was successful in 86% of cases, with suppression in 36% and remission in 64% of 
these patients. Due to the small patient numbers and short follow-up period, definitive 
conclusions could not be made. These results however, appeared comparable to those 
achieved in our retrospective series, with no significant difference in the success rate when 
comparing the prospective and retrospective series (two-sample test p-value=0.877). 
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Through the selection of patient-matched treatment options we were able to close the gap in 
successful outcomes between healthy and compromised patients.19 The success we achieved 
in these studies was therefore probably not the result of surgical or therapeutic prowess, but 
most likely due to appropriate treatment strategy selection. In addition the integrated approach 
places particular emphasis on risk factor modification and host optimization. 
9.4. Other findings and contributions in the field 
Secondary aims of the study included the assessment of the outcome of palliative treatment, 
as well as the outcome of treatment of adult chronic osteomyelitis in HIV positive patients. 
9.4.1. Palliative care outcomes 
There is very little data available on the outcome of palliative treatment in chronic 
osteomyelitis. While promising results have been reported in patients with periprosthetic joint 
infections, no studies have looked specifically at the outcome of palliative treatment in non-
arthroplasty related infections.21 Drancourt et al. reported “cure” in six out of the nine patients 
with osteosynthesis implant related sepsis that were treated with antibiotics alone for a period 
of six months.22 Stein et al. reported “cure” in 60% of patients treated with antibiotics without 
surgical removal of the implants.23 The authors, however, did not distinguish between joint 
replacement and osteosynthesis implant related sepsis in their study.  
In our retrospective series (Chapter 7), successful palliation (defined as the resolution of 
infection to the extent that the patient was satisfied with the outcome and required no further 
treatment) was achieved in 87% of patients (n=48). Of these patients, 25% were A or B-hosts 
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who had minimal impairment and no sequestrum or implant present. Remission (defined as 
the absence of any signs of infection) was achieved in 62% of patients in the palliative group, 
which is similar to the rate of “cure” that was reported by Stein et al.23 The majority of 
patients received only chronic suppressive antibiotic therapy, in the form of co-trimoxazole 
and rifampicin, for a period of three to twelve months. A small number of patients (4%) 
received intralesional debridement in addition to chronic suppressive antibiotic therapy in 
order to successfully achieve suppression.  
These findings suggest that successful palliation can be achieved in a large proportion of 
appropriately selected cases. Chronic suppressive antibiotic therapy may tip the scale in 
favour of the patient, allowing the immune system to suppress the infection in certain 
compromised hosts. Furthermore, many of the risk factors, defining a patient as a C-host, are 
modifiable. Instituting a palliative treatment strategy in these patients may thus buy sufficient 
time for risk factor modification and host optimization to allow subsequent curative 
intervention. In cases were curative surgery is not feasible, chronic suppressive antibiotics 
may also be a useful alternative to ablative surgery.  
With the potential for the recurrence of infection up to 50 years later, our study did not have a 
sufficiently long follow-up period to detect all possibly recurrences and it is likely that there 
will be an increase in the incidence of recurrence on the long term. Patients are counselled 
regarding this eventuality at completion of treatment and antibiotic therapy is re-instituted in 
the case of recurrence. Fifty-three percent of patients treated palliatively in our retrospective 
series required continuation of antibiotic therapy for longer than six months, due to the 
recurrence or persistence of infection. Approximately half of these patients required 12 
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months of treatment and the other half were placed on chronic suppressive antibiotic therapy 
on a permanent basis. This illustrates that, if host modification is unable to change the host 
status to the extent that curative treatment becomes possible, long-term suppressive antibiotic 
therapy may be required in order to achieve and maintain suppression. It is noteworthy that 
only two patients, in the prospective and retrospective series combined, required alteration of 
the chronic suppressive antibiotic therapy regime due to gastrointestinal side effects, which 
suggests that it is well tolerated in the majority of patients  
9.4.2. The outcome of palliative treatment in chronic haematogenous osteomyelitis 
The appropriate treatment of acute haematogenous osteomyelitis has resulted in a drastic 
decrease in the incidence of chronic osteomyelitis of haematogenous origin in the developed 
world.1,18 It is however, still common in under-developed regions and the outcome of 
palliative treatment in compromised hosts with chronic haematogenous osteomyelitis have not 
previously been reported.24  
In our retrospective series we were able to achieve successful suppression of the disease in all 
patients with haematogenous osteomyelitis treated palliatively (n=5). This finding suggests 
that chronic osteomyelitis without the presence of surgical implants can successfully be 
treated palliatively in appropriately selected patients. Again, there is likely to be a high 
recurrence rate and long-term studies will be required to determine the incidence and 
frequency of recurrence of symptomatic infection. 
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9.4.3. The outcome of treatment in patients living with HIV 
To the best of our knowledge the outcome of treatment in patients with HIV/AIDS has not 
previously been investigated. In Chapter 7 we report the outcome of treatment in 33 adult 
HIV positive patients with chronic osteomyelitis. Overall, the success rate in HIV positive 
patients was 84.8% or 28/33 (95%CI:	  68.1-94.9% ).There was no statistically significant 
difference in outcome of treatment (i.e. failure rate) between HIV positive and negative 
patients (Pearson chi-square p-value=0.248).There was a trend towards treatment failure in 
patients with a CD4 count below 350 cells/mm3 (Fishers exact p-value=0.083). 
All treatment failures, in the HIV positive group, occurred in patients who fulfilled the World 
Health Organization immunological criteria for advanced disease (CD4 count < 350 cells/
mm3).25 It is, however, also important to note that the majority of HIV positive patients were 
treated through either a palliative or alternative treatment strategy. Curative treatment was 
successful in three out of the four HIV positive patients in whom it was employed. 
These findings suggest that palliative treatment may be successful in appropriately selected 
HIV positive patients. Because of the small patient numbers, firm conclusions could not be 
made in terms of the outcome of curative treatment. Failure occurred in only one of the four 
patients that were treated curatively. In this case, failure was not the result of recurrence of 
infection, but the result of the patient’s unwillingness to complete the bone transport process 
(opting rather for amputation). Taking the aforementioned into account, it appears that 
curative treatment may also be successful and should not be excluded as an option purely on 
the basis of HIV infection alone. 
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9.5. Limitations 
While the proposed integrated approach may offer several advantages and appears to have 
delivered promising results, there are several limitations to the studies contained within this 
thesis. The most apparent of these relate to the short follow-up periods in the three clinical 
studies (Chapters 6-8). Owing to the unique characteristics of the causative organisms, 
reactivation of chronic osteomyelitis may occur as much as 65 years following the initial 
infection.26,27 Our results are therefore likely to deteriorate over time due to the recurrence of 
infection. In the palliative treatment group in particular, recurrence can be expected. Our 
current treatment protocol is to inform patients of the likelihood of recurrence and to reinstate 
chronic suppressive antibiotics when needed. Longer follow-up will be require to determine 
the frequency of recurrence in the respective treatment groups. 
There are several potential advantages to the use of PMMA spacers as dead space 
management tool in patients with large post-infective bone defects. The small sample size and 
lack of control group of the study in Chapter 6 however, prohibited drawing firm conclusions 
in this regard. No clear advantage could be shown in terms of the external fixation index, 
which in actual fact appeared to be higher than in other studies using traditional Ilizarov 
techniques. The findings of this study did however emphasize the importance of surgical 
candidate selection and the fact that failure of complex reconstructive procedures (involving 
bone transport) may result in amputation. 
Other limitations of the retrospective study investigating the outcome of treatment according 
to an integrated approach (Chapter 7) include the absence of a control group and lack of 
randomization. The lack of randomization would however, be difficult to overcome. Exposing 
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all patients, including the most compromised hosts, to the rigours of limb salvage surgery in 
order to see which risk factors are associated with treatment failure (which may involve 
amputation) would represent an ethical dilemma. The fact that we defined success differently 
in the curative and palliative groups resulted in an apparent improvement in results. However, 
it would be unrealistic to expect cure (clinical, biochemical and radiological absence of 
infection) in palliated patients and thus the definition of success or failure of treatment is 
intimately bound to the management strategy selected. The final shortcoming of this study 
was its retrospective nature, which prompted the design of a prospective study to validate the 
results. 
The main limitation of the prospective series, investigating the outcome of treatment 
according to the integrated approach (Chapter 8), was again the short follow-up period. 
Deterioration of results is likely to occur with longer follow-up. The lack of a control group 
and randomization presented similar difficulties to those found in the retrospective series. The 
use of standardized host stratification criteria may, however, enable the comparison of our 
results with those of future studies. The final limitation is the small sample size. Due to the 
heterogenous nature of the disease and patient profile a larger series would be required to 
determine if the algorithm is truly appropriate in all possible clinical scenarios. 
9.6. Future directions 
The primary aim of this project was to introduce the concept of pragmatic host stratification, 
which could potentially facilitate and standardize treatment pathway selection. The ideas 
introduced in this thesis still require additional validation and development. A large multi-
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centre prospective trial would provide further validation of the suggested approach. In 
accordance with these results the treatment algorithm may have to be adapted to include all 
possible clinical presentations and treatment options. Proposals for the management of cases 
where the initial treatment strategy failed may also need to be added. 
A particular problem group is the C-host with unstable (type IV) chronic osteomyelitis. The 
distinction between a patient who requires amputation or alternative treatment strategy needs 
to be clarified. According to our approach, this decision was based on the physician 
assessment of the potential to achieve union. This guideline however lacks sufficient 
objectivity to be reproducible and further criteria will need to be developed to guide treatment 
strategy selection in C-hosts with septic non-union.  
A second area of ambiguity in the proposed treatment algorithm relates to the rating of 
impairment. Diagnosis-based impairment rating according to the American Medical 
Association (AMA) Guides to the Evaluation of Permanent Impairment (6th edition) was 
found not to be sufficiently specific, as most infections were rated as class 4 (very severe) 
impairment.28 The functional history adjustment ratings proposed by the AMA Guides 
however, appeared to be more appropriate as a guide to treatment selection. As suggested by 
the AMA Guides , the AAOS Lower Limb Outcomes Instrument and quickDASH was used to 
perform functional symptom assessment in the lower and upper limbs respectively. While 
these objective scoring systems were used to determine impairment in our prospective series, 
the small sample size prohibited the establishment of discreet cut-off points.  
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The list of risk factors may also need to be expanded and further stratification of individual 
risk factors may be required in order to render the approach valid in all patients. Several 
additional risk factors were, for example, identified in the retrospective series (Chapter 7). 
The weighting of each risk factor, or a combination of certain risk factors, will also need 
further consideration. In one case in our prospective series (Chapter 8) the treatment 
algorithm may have been too conservative by prescribing chronic suppressive antibiotic 
therapy in a case where amputation was probably inevitable. 
It also remains unclear if the suggested approach will be applicable beyond South Africa. 
Although preliminary results appear promising, caution is still advisable with regard to the 
widespread implementation of this approach. The treatment selection pathways were 
developed and tested in the developing world. Extrapolation to regions with a lower number 
of C-hosts may require further improvement or modification of the approach  
In principle there are several potential advantages to pragmatic treatment strategy selection. 
The most relevant of these is the fact that standardized host stratification may enable the 
comparison of results from future studies. It may thus become possible to compare the 
outcome of different interventions or strategies, if the physiological status of the host was 
classified according to same pre-defined pragmatic criteria. In turn this may allow us to 
answer many of the questions that remain in the management of adult chronic osteomyelitis.19 
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9.7. Conclusion 
Through the integration of a modified host stratification system with treatment strategy 
selection, in an algorithmic approach, we achieved favourable outcomes in both high and low 
risk patients. In addition we were able to maintain a relatively low amputation rate, which is 
particularly relevant to our resource-poor clinical environment.  
Although this approach was specifically designed for use in the South African setting, the 
principle of defining the host status according to pragmatic diagnostic criteria may also be 
useful elsewhere, as it would enable the comparison of results of different therapeutic 
interventions. 
Finally, instituting a palliative treatment strategy in high-risk patients creates an opportunity 
for risk factor modification and host optimization, which may allow subsequent curative 
intervention. While our preliminary results are promising, further prospective research and 
follow-up is required in order to assess long-term outcomes and validity of the suggested 
treatment algorithm.  
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